

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Relationship between Hospital Performance Measures and Stroke Outcomes in Patients with Acute Ischemic Stroke

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020467
Article Type:	Research
Date Submitted by the Author:	13-Nov-2017
Complete List of Authors:	<p>Zhang, Xinmiao; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Li, Zixiao; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Zhao, Xingquan; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Xian, Ying; Department of Neurology, Duke Clinical Research Institute, Duke University,</p> <p>Liu, Liping; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Wang, Chunxue; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Wang, Chunjuan; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Li, Hao; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Prvu Bettger, J; Department of Neurology, Duke Clinical Research Institute, Duke University; Duke University School of Nursing, Duke University</p> <p>Yang, Qing; Duke University School of Nursing, Duke University</p> <p>Wang, David; INI Stroke Network, OSF Healthcare System, University of Illinois College of Medicine</p> <p>Jiang, Yong; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Bao, Xiaolei; Statistical Analysis Office, Department of Information, General Hospital of Lanzhou Military Area Command</p> <p>Yang, Xiaomeng; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Wang, Yilong; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Wang, Yongjun; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Diseases
Primary Subject Heading:	Neurology
Secondary Subject Heading:	Evidence based practice
Keywords:	Ischemic stroke, Quality and Outcomes, Mortality, Hospital performance

SCHOLARONE™
Manuscripts

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2017-020467 on 1 August 2018. Downloaded from <http://bmjopen.bmj.com/> on April 20, 2024 by guest. Protected by copyright.

Title pages**Relationship between Hospital Performance Measures and Stroke Outcomes in Patients with
Acute Ischemic Stroke**

Xinmiao Zhang^{1,2,3,4,#}; Zixiao Li^{1,2,3,4,#}; Xingquan Zhao^{1,2,3,4}; Ying Xian⁵; Liping Liu^{1,2,3,4};
Chunxue Wang^{1,2,3,4}; Chunjuan Wang^{1,2,3,4}; Hao Li^{1,2,3,4}; Janet Bettger^{5,6}; Qing Yang⁶; David
Wang⁷; Yong, Jiang^{1,2,3,4}; Xiaolei Bao⁸; Xiaomeng Yang^{1,2,3,4}; Yilong Wang^{1,2,3,4,*}; Yongjun
Wang^{1,2,3,4,*}; on behalf of China National Stroke Registries

¹ Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

² China National Clinical Research Center for Neurological Diseases, Beijing, China

³ Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China

⁴ Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China

⁵ Department of Neurology, Duke Clinical Research Institute, Duke University, Durham, NC, USA

⁶ Duke University School of Nursing, Duke University, Durham, NC, USA

⁷ INI Stroke Network, OSF Healthcare System, University of Illinois College of Medicine, Peoria, IL,
USA

⁸ Statistical Analysis Office, Department of Information, General Hospital of Lanzhou Military Area
Command, Lanzhou, Gansu, China

* The first two authors contributed equally to this work.

*** Correspondence to:**

Corresponding author: Yongjun Wang

Address: No.6 Tiantanxili, Dongcheng District, Beijing, China, 100050

Work telephone: +86 010-67098350

Fax: +86 010-67013383

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

E-mail address: yongjunwang1962@gmail.com

Co-corresponding author: Yilong Wang

E-mail: yilong528@gmail.com

Key words: Hospital performance; Ischemic stroke; Quality and Outcomes; Mortality

Word count: 3362

For peer review only

Relationship between Hospital Performance Measures and Stroke Outcomes in Patients with Acute Ischemic Stroke

ABSTRACT

Objectives: Guideline-recommended performance measures were increasingly used to evaluate hospital quality of stroke care, but their impact on stroke outcome has not been verified. We aimed to evaluate the correlation between hospital performance measures and outcomes among acute ischemic stroke patients.

Methods: Data was derived from 120 hospitals participating in the China National Stroke Registry between September 2007 and August 2008. Adherence to 9 guideline-recommended performance measures was examined, and the composite score of hospital performance measures was calculated. Primary stroke outcomes were hospital-level, 30-day and 1-year risk-standardized mortality (RSM). Association of hospital individual performance measures and composite score with stroke outcomes was assessed by using Pearson correlation coefficients.

Results: The overall composite score of performance measures was 63.3%. The correlations coefficients between individual performance measures ranged widely from 0 to 0.87. The composite score was modestly associated with 30-day and 1-year RSM (Pearson correlation coefficients, 0.23 and 0.34, respectively; $P < 0.05$ for both), and explained only 5.24% and 11.80% of hospital-level variation in 30-day and 1-year RSM for acute stroke patients.

Conclusions: The adherence to guideline-recommended performance measures for acute ischemic stroke was suboptimal in China. There were various correlations among hospital individual performance measures. The association of hospital performance measures with hospital-level short- and long-term mortality rates was modest.

Article summary

Strengths and limitations of this study:

1. This study found that the adherence to guideline-recommended performance measures for acute ischemic stroke was suboptimal in China.
2. The association of hospital performance measures with hospital-level short- and long-term mortality rates was modest.
3. The study was limited that results reported herein came from the Chinese healthcare system and therefore may not necessarily be generalisable to other countries.

INTRODUCTION

Guideline-recommended hospital performance measures are increasingly used for quality improvement,¹ certification for stroke centres,² public reporting³ and remuneration for performance.⁴ Performance measures evaluate the structure, process and outcome of care, and provide a metric that can be tracked, reported and improved.⁵ Although performance measures have been associated with higher scores on measured metrics,⁶ there has been limited evidence demonstrating an association between adherence to performance measures and better patient outcomes.⁷

Using data from the China National Stroke Registry (CNSR), we sought to determine whether evidence-based hospital performance measures were associated with short- and long-term outcomes in acute ischemic stroke patients in China. Specifically, we (1) reported the hospital variation in adherence to evidence-based performance measures, (2) assessed the correlation between each individual performance measures, and (3) quantified the association between performance measures and hospital-level, risk-standardised, 30-day and 1-year mortality among acute ischemic stroke patients in China.

METHODS

CNSR overview

The CNSR was the first nationwide, hospital-based, prospective stroke registry of quality assessment in China. It was sponsored by the Ministry of Health of the People's Republic of China to establish a national stroke database for evaluating stroke care quality and outcomes, and conducted between September 2007 and August 2008. The study design of CNSR has been described previously.⁸ Briefly, the criteria used for hospital selection included: (1) having at least one stroke neurologist, (2) at least two sites were included from each of the 31 provinces and municipalities in mainland China, (3) commitment to participate voluntarily and (4) ability to conduct research.^{8,9} The CNSR recruited

1
2
3 consecutive patients older than 18 years and diagnosed with ischemic stroke, transient ischemic
4 attack (TIA), intracerebral haemorrhage, or subarachnoid haemorrhage within 14 days of the index
5
6 event. We collected patients' demographics, adherence to performance measures in hospitals, and
7
8 status at discharge, 90-day, 6-month and 1-year follow-up after symptom onset. The study was
9
10 approved by the Central Institutional Review Board of CNSR. Written informed consent was
11
12 acquired from the patient or legally authorised representative.
13
14
15

16 17 18 **Data collection**

19
20 Hospitals' characteristics were surveyed. According to annual report on health statistics of China,¹⁰
21
22 hospitals were divided into three regions: eastern, central and western. Academic status was defined
23
24 as a hospital affiliated with a specific university. Hospital bed size was the number of total inpatient
25
26 beds per site. Annual stroke discharge was the number of discharged patients diagnosed with stroke
27
28 per year per hospital.
29
30
31

32
33 Trained research coordinators at each hospital reviewed medical records daily to identify, obtain
34
35 informed consent, and enrol consecutive patients in accordance with the procedures indicated in a
36
37 standard data collection manual. The key variables in the CNSR were assessed, including: (1)
38
39 demographic characteristics and medical history; (2) pre-stroke modified Rankin scale (mRS), and
40
41 National Institutes of Health Stroke Scale (NIHSS) at admission, vascular risk factors, and clinical
42
43 care during hospitalization and (3) 30-day and 1-year all-cause mortality after stroke. Patients who
44
45 survived to discharge, or their authorised caregivers, were contacted via telephone by trained
46
47 research personnel who used standardised scripts for follow-up at 90 days, 6 months and 1 year after
48
49 stroke symptom onset⁸. Specific death events and dates were recorded in detail, and 30-day and
50
51 1-year all-cause mortality after stroke were confirmed.
52
53
54
55
56
57
58
59
60

Performance Measures

We evaluated nine hospital performance measures, including six “core” measures for acute ischemic stroke as recommended by American Heart Association/American Stroke Association (AHA/ASA) Get With The Guidelines-Stroke (GWTG-Stroke)¹¹ and three additional guideline-recommended secondary prevention metrics.¹² These nine performance measures included three acute performance measures: (1) intravenous tissue-type plasminogen activator (tPA) in patients who arrive within 2 hours after symptom onset and treated within 3 hours (IV rt-PA for 2 Hour), (2) antithrombotic medication within 48 hours of admission (early antithrombotics), (3) deep vein thrombosis (DVT) prophylaxis within 48 hours of admission for nonambulatory patients (DVT prophylaxis); and 6 discharge performance measures: (1) antithrombotic medication, (2) anticoagulation for atrial fibrillation (AF), (3) antihypertensive medication for patients with hypertension, (4) medications for lowering low-density lipoprotein (LDL) ≥ 100 mg/dL, (5) hypoglycemia medication for diabetes mellitus, (6) smoking cessation. Details of the performance measures were described in the Table 1.

Adherence to hospital-level individual performance measures was calculated as the proportion of patients who received the indicated care from among all the patients who were eligible for the indicated care. The overall hospital performance measures was measured as the composite score, which was calculated by the total number of interventions actually performed among all eligible patients at a hospital, divided by the total number of recommended interventions in all eligible patients.¹³ Although the composite score was analysed as a continuous variable, hospitals were also divided, for descriptive purposes, into quartiles based on this continuous variable. To ensure the stability of the measure, hospitals with fewer than 20 patients in the denominator of a measure were excluded.

Table 1. Specifications of guideline-recommended performance measures

Performance measure of ischemic stroke care	Performance measure definition for eligible patients*
Acute performance measures	
IV rt-PA <2 Hour	Intravenous recombinant tissue plasminogen activator (IV rtPA) in patients who arrive within 2 hours after initial symptom onset and treated within 3 hours
Early Antithrombotics	Antithrombotic therapy prescribed within 48 hours of hospitalization, including antiplatelet or anticoagulant therapy
DVT Prophylaxis	Patients at risk for deep vein thrombosis (DVT) (non-ambulatory) who received DVT prophylaxis by end of hospital day two, including pneumatic compression, warfarin sodium or heparin sodium
Performance measures at discharge	
Discharge Antithrombotics	Antithrombotic therapy prescribed at discharge
Anticoagulation for Atrial Fibrillation	Anticoagulation prescribed at discharge for patients with atrial fibrillation or atrial flutter documented during the hospitalization
LDL 100	Lipid lowering agent prescribed at discharge if Low-density lipoprotein (LDL) ≥ 100 mg/dL
Antihypertension for hypertension disease:	Antihypertension medication prescribed at discharge for patients with history of hypertension disease or hypertension

	disease documented during the hospitalization
Hypoglycemic therapy for	Hypoglycemic medication prescribed at discharge for patients
diabetes mellitus:	with history of diabetes mellitus or diabetes mellitus
	documented during the hospitalization
Smoking Cessation	Smoking cessation intervention (counseling or medication)
	prior to discharge for current or recent smokers

* Eligible patients are those without any medical contraindications (e.g., treatment intolerance, excessive risk of adverse reaction, patient/family refusal, or terminal illness/comfort care only) documented as reasons for nontreatment for each of the applicable measures. Also excludes patients who are discharged to hospice, or another short-term general hospital, leave against medical advice before the end of hospital day two. For acute performance measures except for rt-PA measure, excludes patients who died before the end of hospital day two. The acute rt-PA measure excludes patients with missing or erroneous onset, arrival or treatment times, those who began IV t-PA at an outside hospital, or who initiated IV t-PA after 180 minutes from onset. For performance measures at discharge, excludes patients who died during hospitalization. As for six performance measures from Get With The Guideline-Stroke (GWTG-Stroke), we employed the same criteria as the Get With The Guideline-Stroke (GWTG-Stroke).

Risk-standardized Mortality (RSM) Rates

RSM rates were calculated using a multivariate hierarchical regression model in accordance with the AHA/ASA recommendations for risk adjustment of ischemic stroke outcomes to compare hospital performance.⁷ The first level of the hierarchical model included patient characteristics. These patient's variables were divided into three categories: (1) demographics and clinical features: age, gender, health insurance type (urban basic medical insurance schemes for urban and governmental employees and urban residents, new rural cooperative medical schemes for rural residents, commercial insurance, and self-payment), transport to hospital by emergency medical service, and NIHSS score at admission; (2) vascular risk factors: hypertension, diabetes mellitus, dyslipidaemia, AF, coronary artery disease, previous myocardial infarction, congestive heart failure, valvular heart disease, history of stroke/TIA, peripheral vascular disease, current smoking, and excessive alcohol consumption; (3) other pre-existing comorbid conditions: chronic obstructive pulmonary disease, hepatic cirrhosis, peptic ulcer, previous gastrointestinal bleeding, Alzheimer's disease/dementia, cancer, DVT/pulmonary embolus, renal dialysis, pre-stroke dependence (mRS ≥ 3), and blood glucose at admission. The second level included hospital-specific random intercepts that allow for different baseline mortality rates between hospitals. The hospital RSM rates were obtained as the ratio of "predicted" to expected mortality, multiplied by the unadjusted mortality rate for the total population.^{14 15} The expected outcome for each hospital was the number of deaths expected at the hospital if the hospital's patients were treated at a "reference" hospital. The predicted hospital outcome was the number of expected mortalities at the "specific" hospital and not at a reference hospital. To ensure the stability of the measure, hospitals with fewer than 20 patients in the denominator of a measure were excluded.

Statistical analyses

Numbers (percentages) were used to describe categorical variables, and median values with interquartile ranges (IQRs) were reported for continuous variables. The correlations of individual performance measures, as well as performance measures and stroke outcomes, were evaluated using Pearson correlation coefficients. We reported both the relevant correlation coefficients and the percentage of the hospital-specific variation in RSM rates was explained; i.e., the squares of the correlation coefficients as indicators of the strength of the associations.¹⁶

All tests were two-tailed, and statistical significance was determined at the α level of 0.05 in univariate and multivariate analyses. Statistical analysis was performed using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).

RESULTS

Study hospitals and patient baseline characteristics

Among 14,526 eligible patients diagnosed with acute ischemic stroke from 132 hospitals throughout China, complete 1-year follow-up information was available for 12,173 patients (83.8%). We excluded 12 hospitals with fewer than 20 patients in the denominator of a measure. Finally, 120 hospitals that recruited 12,027 patients with ischemic stroke were included in our analysis. Hospital and patient baseline characteristics were described in Table 2. Among 120 hospitals, 62 (51.67%) hospitals were teaching hospitals and 70 (58.33%) were from eastern regions. The median hospital bed size was 1200 (range, 700–1861) and annual stroke volume was 430 (range, 310–601). Among 12,027 patients, 7407 (61.59%) were men, and the median age was 67 (range, 57–75) years. Common vascular risk factors included hypertension, previous stroke/ TIA, smoking history, and diabetes. The median NIHSS score was 4 (range, 2–9).

Variability in performance measures

The overall composite score was 63.3% among the 120 hospitals. However, the composite score for each hospital varied considerably among the CNSR (Table 3). The hospitals in the highest quartile (quartile 4) had a median (IQR) composite score of 85.1% (82.2%–89.9%), compared with 50.9% (44.2%–58.1%) for those in the lowest quartile (quartile 1).

Table 3 also shows the variability in adherence to individual guideline-recommended performance measures among patients without contraindications. Within acute interventions, early antithrombotics showed the lowest degree of variance, although the difference between the first and third quartiles remained significant. In contrast, there were twofold to threefold differences in the use of IV rt-PA for 2 Hour, DVT prophylaxis, anticoagulant for AF and lipid-lowering medication for LDL \geq 100 mg/dl.

Table 2. Baseline characteristics of patients with acute ischemic stroke among China National Stroke Registry

	Level	N (%)
Patient characteristics		
Total		
12 027		
Demographics		
Age, yr	Median (IQR)	67 (57-75)
Gender	Male	7 407(61.59)
	Female	4 620(38.41)
Insurance scheme	UBMIS	7 311(60.79)
	NRCMS	2 027(16.85)

	Commercial	397(3.30)
	Self-payment	2 292(19.06)
Transport to hospital by EMS	Yes	1 901(15.81)
NIHSS at admission	Median (IQR)	4 (2-9)
Vascular risk factors		
Previous stroke/TIA	Yes	4 088(33.99)
Diabetes	Yes	2 593(21.56)
Hypertension	Yes	7 672(63.79)
Dyslipidemia	Yes	1 344(11.17)
CHD/previous MI	Yes	1 748(14.53)
Atrial fibrillation	Yes	892(7.42)
PVD	Yes	76(0.63)
Ever Smoking	Yes	4 779(39.74)
Heavy drinking	Yes	1 873(15.57)
Pre-existing comorbid condition		
Congestive heart failure	Yes	250(2.08)
Valvular Heart Disease	Yes	288(2.42)
Chronic obstructive pulmonary disease	Yes	138(1.15)
Hepatic cirrhosis	Yes	41(0.34)
Peptic ulcer disease	Yes	336(2.81)
Previous gastrointestinal bleeding	Yes	184(1.54)
Dementia/Alzheimer's disease	Yes	156(1.30)

Cancer	Yes	215(1.80)
Deep venous thrombosis/Pulmonary embolus	Yes	77(0.64)
Renal Dialysis	Yes	9(0.08)
Pre-stroke dependence (mRS>2)	Yes	1 120(9.31)
Glucose on admission (≥ 7.5 mmol/L)	Yes	2 328(19.72)
Hospital characteristics		
Total		120
Hospital size		
Beds	Median (IQR)	1 200 (700, 1 861)
Hospital type		
Teaching	Yes	62(51.67)
Annual stroke discharges	Median (IQR)	430 (310,601)
Geographic region		
East	Yes	70 (58.33)
Middle	Yes	26 (21.67)
West	Yes	24 (20.0)

IQR, interquartile range; UBMIS, urban basic medical insurance scheme; NRCMS, new rural cooperative medical scheme; EMS, emergency medical service; NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischemic attack; CHD, coronary artery disease; MI, myocardial infarction; PVD, peripheral vascular disease; mRS, modified Rankin scale.

Table 3. Hospital performance measures and RSM rates

Measures	25 th Percentile	Median	75 th Percentile
Composite score	59.05%	65.65%	72.75%
Acute interventions			
IV rt-PA for 2 Hour	0.00%	0.00%	25.00%
Early antithrombotics	73.21%	80.68%	88.24%
DVT prophylaxis	33.33%	59.22%	70.00%
Discharge interventions			
D/C antithrombotics	64.89%	77.00%	85.15%
Anticoagulation for AF	0.00%	14.29%	26.97%
Lipid-lowering drug for LDL \geq 100 mg/dl	25.00%	41.89%	61.72%
Antihypertensive Medication	45.46%	61.37%	75.00%
Antidiabetic Medication	53.15%	67.03%	79.58%
Smoking cessation	50.55%	70.87%	83.33%
RSM rate			
30-day	4.91%	5.41%	6.17%
1-year	12.77%	13.55%	14.48%

IV, intravenous; rt-PA, recombinant tissue-type plasminogen; DVT, deep vein thrombosis; D/C, discharge; AF, atrial fibrillation; LDL, low-density lipoprotein; RSM, risk-standardised mortality.

Correlations of performance measures

The correlations between two individual hospital performance measures varied widely (Table 4). We found moderate correlation (Pearson correlation coefficient ≥ 0.40 ; $P < 0.001$ for all) for all pairwise comparisons between antithrombotic at discharge and early antithrombotics, lipid-lowering drugs for LDL ≥ 100 mg/dl, antihypertensive medication, antidiabetic medication, and smoking cessation at discharge; and between antidiabetic medication and antihypertensive medication and smoking cessation at discharge. Other hospital performance measures had a modest correlation or no correlation with each other (Pearson correlation coefficient < 0.40 for all).

Association of performance measures with hospital-level RSM rates

The median 30-day and 1-year RSM rate (IQR) was 5.41% (4.91%–6.17%) and 13.55% (12.77%–14.48%), respectively (Table 3).

Several performance measures showed a statistically significant, but modest, correlation with 30-day and 1-year RSM rates, including antithrombotics at discharge (Pearson correlation coefficients = 0.21 and 0.33, respectively), antihypertensive medication (Pearson correlation coefficients = 0.24 and 0.37, respectively) and antidiabetic medication (Pearson correlation coefficients = 0.33 and 0.36, respectively) ($P < 0.001$ for all) (Table 4). These performance measures individually explained between 4.38% and 10.59% of hospital-level variation in 30-day RSM rates, and between 10.58% and 14.01% of hospital-level variation in 1-year RSM rates (Table 5).

The hospital-level composite score had a modest correlation with 30-day and 1-year RSM rates (Pearson correlation coefficients = 0.23 and 0.34, respectively) (Table 4), and explained 5.24% and 11.80% of the hospital-level variation in 30-day and 1-year RSM rates, respectively (Table 5).

Table 4. Correlation coefficients for performance measures and hospital RSM rate (30-day and 1-year)

	Acute interventions			Discharge interventions						
	IV rt-PA for 2 Hour	Early antithrombotics	DVT prophylaxis	Antithrombotics	Anticoagulation for AF	Lipid-lowering drug for LDL ≥ 100 mg/dl	Antihypertensive Medication	Antidiabetic Medication	Smoking cessation	Composite score
Acute interventions										
IV rt-PA for 2 Hour	1.00									
Early antithrombotics	-0.06	1.00								
DVT prophylaxis	-0.02	0.28*	1.00							
Discharge interventions										
Antithrombotics	0.06	0.40*	0.07	1.00						
Anticoagulation for AF	-0.02	0.00	0.07	0.27*	1.00					
Lipid-lowering drug for LDL ≥ 100 mg/dl	0.07	0.03	-0.06	0.45*	0.22*	1.00				
Antihypertensive Medication	0.09	0.12	-0.05	0.64*	0.20*	0.27*	1.00			
Antidiabetic Medication	0.18*	0.17	0.05	0.79*	0.14	0.39*	0.71*	1.00		
Smoking cessation	0.14	0.25*	0.02	0.43*	0.19*	0.13	0.37*	0.42*	1.00	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Composite score	0.10	0.55*	0.27*	0.89*	0.29*	0.50*	0.70*	0.77*	0.58*	1.00
Risk-standardized 30-day mortality rate	-0.13	-0.01	-0.15	-0.21*	-0.09	-0.22*	-0.24*	-0.33*	0.05	-0.23*
Risk-standardized 1-year mortality rate	-0.09	-0.08	-0.15	-0.33*	-0.10	-0.13	-0.37*	-0.36*	-0.07	-0.34*

IV, intravenous; rt-PA, recombinant tissue-type plasminogen; DVT, deep vein thrombosis; AF, atrial fibrillation; LDL, low-density lipoprotein; RSM, risk-standardised mortality.

*P<0.05.

For peer review only

Table 5. Variance in 30-day and 1-year RSM rates explained by each performance measure and composite measure

	30-day RSM rate	1-year RSM rate
Measures	% variance explained	% variance explained
Acute interventions		
IV rt-PA for 2 Hour	1.77%	0.84%
Early antithrombotics	0.02%	0.59%
DVT prophylaxis	2.28%	2.25%
Discharge interventions		
D/C antithrombotics	4.31%	10.58%
Anticoagulation for AF	0.86%	0.95%
Lipid-lowering drug for LDL	4.66%	1.64%
≥100 mg/dl		
Antihypertensive Medication	5.98%	14.01%
Antidiabetic Medication	10.59%	13.09%
Smoking cessation	0.24%	0.43%
Composite score	5.24%	11.80%

IV, intravenous; rt-PA, recombinant tissue-type plasminogen; DVT, deep vein thrombosis; D/C, discharge; AF, atrial fibrillation; LDL, low-density lipoprotein; RSM, risk-standardised mortality.

DISCUSSION

The present study found that ischemic stroke care was suboptimal in China and there were various correlations among hospital performance measures. The hospital-level composite score had a modest correlation with 30-day and 1-year RSM rates. This finding suggested hospital performance measures cannot reliably infer short- and long- term mortality rates after acute ischemic stroke. Our results underscored that the current performance measures of stroke care provided complementary, but not redundant, information with the measures of 30-day and 1-year mortality.

The relationship between performance measures and stroke outcomes still exists uncertainty. Some studies have indicated the use of performance measures was associated with lower short-term mortality or better functional outcomes.¹⁷⁻¹⁹ However, the link between stroke performance measures and outcome was not straightforward in certain other studies.²⁰⁻²³ There were several probable reasons for the modest correlation between hospital-level performance measures and risk-standardised mortality in the present study. First, although clinical trials have shown a significant relationship between process interventions and outcomes,^{24 25} the guideline-recommended performance measures were not mainly designed to be a substitute for overall short- and long-term hospital mortality. Second, there was relative little variation across hospitals in some performance measures, such as early antithrombotics after admission, which limited the ability to discriminate between hospitals based on their performance on this measure. Additionally, some performance measures, such as intravenous thrombolysis, may had a greater effect regarding stroke-related disability than that in stroke-related mortality.²⁶ Finally, hospital mortality rates, even risk-standardised ones, were likely affected by many factors independent of the performance measures of stroke care quality. These included severity of stroke, patients' or their family's

1
2
3 preference, economic level and clinical strategies that may contribute to a hospital's performance
4
5 outcomes.²⁷
6
7

8 The present study also demonstrated a significant correlation between certain
9
10 guideline-recommended performance measures for acute ischemic stroke care, indicating the
11
12 hospitals that perform well in one performance measure were likely to perform well in the others.
13
14 However, other performance measures were less strongly correlated with each other. This finding
15
16 implies different performance measures reflect separate components of quality in acute ischemic
17
18 stroke care. Our work indicated that hospital performance rankings were likely to be substantially
19
20 affected by the performance measures under selection. A broad range of performance measures
21
22 appears necessary to comprehensively reflect hospital care practices.
23
24
25
26
27

28 Our study had several strengths. First, to date, the CNSR was the largest stroke database in China.
29
30 Hospitals participating in the CNSR encompassed different regions and had good representativeness.
31
32 Second, we used newer RSM methods based on hierarchical models to account for variation in case
33
34 numbers across hospitals or for intra-hospital clustering effects.⁷ Third, baseline characteristics of
35
36 patients, such as age, gender, vascular risk factors, comorbid conditions, and stroke severity (NIHSS)
37
38 were adjusted in calculating the RSM in accordance with the American Heart Association/American
39
40 Stroke Association (AHA/ASA).^{7,27} Additionally, besides short-term RSM, our study also analysed
41
42 long-term RSM.
43
44
45
46

47 However, our study also had some limitations. First, our study was observational and
48
49 non-randomised. The association between care processes and stroke outcomes did not necessarily
50
51 prove causality and may be confounded by previously discussed factors. Second, our outcome was
52
53 mortality; other outcomes, such as stroke recurrence and functional outcomes, were also vital to
54
55
56
57

1
2
3 patients and should be assessed in future studies.²³ Third, it remains unclear whether this
4
5 process–outcome link for a given set of performance measures may vary over time. Future research
6
7 need to determine the stability of the process-outcome relationship as quality improvement efforts
8
9 drive broader care adoption. Finally, there were several differences between stroke healthcare
10
11 delivery systems in China and in other countries. The results reported herein came from the Chinese
12
13 healthcare system and therefore may not necessarily be generalisable to other countries.
14
15

16 17 18 **CONCLUSIONS**

19
20 The quality of process care for ischemic stroke was suboptimal in China, and there were various
21
22 correlations in hospital performance among the individual metrics. Although the
23
24 guideline-recommended performance measures were important in pursuing improved acute ischemic
25
26 stroke outcomes, the relationship between performance measures and hospital short- and long-term
27
28 risk-adjusted mortality rates was modest. Much broader measures needed to be used as a means of
29
30 assessing and helping improve the quality of hospital-level stroke care.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

We thank all participating hospitals, colleagues, nurses, imaging and laboratory technicians, and the CNSR Steering Committee members.

Contributorship Statement

XMZ and ZXL analyzed the data and wrote the manuscript. XLB, LPL, CXW, HL, JB, QY and DW analyzed and interpreted the data. ZXL, CJW, YJ, XMY and XMZ performed research. YJW, YLW, ZXL, YX and ZQZ conceived, designed and supervised the study.

Funding

Supported by grants from the Ministry of Science and Technology of the People's Republic of China (2006BA101A11, 2008ZX09312-008, 2011BAI08B01, 2011BAI08B02, 2012ZX09303, 2013BAI09B14, 2013BAI09B03, 2015BAI12B02, and 2015BAI12B04), grants from the Beijing Municipal Science and Technology Commission (D15110700200000, D151100002015001, D151100002015002, Z161100000516223 and Z141107002514125), and the Beijing Tiantan Hospital Seeding Initiative.

Competing interests

None.

Ethics approval

Approval was obtained from the Central Institutional Review Board at Beijing Tiantan Hospital.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement: No additional data are available.

References

1. Ellrodt AG, Fonarow GC, Schwamm LH, et al. Synthesizing lessons learned from get with the guidelines: the value of disease-based registries in improving quality and outcomes. *Circulation* 2013;128:2447-60.
2. Alberts MJ, Latchaw RE, Jagoda A, et al. Revised and updated recommendations for the establishment of primary stroke centers: a summary statement from the brain attack coalition. *Stroke* 2011;42:2651-65.
3. Krumholz HM, Keenan PS, Brush JE, Jr., et al. Standards for measures used for public reporting of efficiency in health care: a scientific statement from the American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research and the American College of Cardiology Foundation. *Circulation* 2008;118:1885-93.
4. Lindenauer PK, Remus D, Roman S, et al. Public reporting and pay for performance in hospital quality improvement. *N Engl J Med* 2007;356:486-96.
5. Measuring and improving quality of care: a report from the American Heart Association/American College of Cardiology First Scientific Forum on Assessment of Healthcare Quality in Cardiovascular Disease and Stroke. *Circulation* 2000;101:1483-93.
6. Schwamm LH, Fonarow GC, Reeves MJ, et al. Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. *Circulation* 2009;119:107-15.
7. Katzan IL, Spertus J, Bettger JP, et al. Risk adjustment of ischemic stroke outcomes for comparing hospital performance: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2014;45:918-44.

- 1
2
3
4 8. Wang Y, Cui L, Ji X, et al. The China National Stroke Registry for patients with acute
5
6 cerebrovascular events: design, rationale, and baseline patient characteristics. *Int J Stroke*
7
8 2011;6:355-61.
9
- 10
11 9. Wang Y, Liao X, Zhao X, et al. Using recombinant tissue plasminogen activator to treat acute
12
13 ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry
14
15 (CNSR). *Stroke* 2011;42:1658-64.
16
17
- 18
19 10. Ministry of health of the people's republic of china . Annual report on health statistics of china
20
21 2010 [in chinese] . Beijing, china : Publishing house of the peking union medical college ;
22
23 2010.
24
- 25
26 11. Fonarow GC, Reeves MJ, Smith EE, et al. Characteristics, performance measures, and in-hospital
27
28 outcomes of the first one million stroke and transient ischemic attack admissions in get with
29
30 the guidelines-stroke. *Circ Cardiovasc Qual Outcomes* 2010;3:291-302.
31
32
- 33
34 12. Wang YJ, Zhang SM, Zhang L, et al. Chinese guidelines for the secondary prevention of
35
36 ischemic stroke and transient ischemic attack 2010. *CNS Neurosci Ther* 2012;18:93-101.
37
- 38
39 13. Peterson ED, DeLong ER, Masoudi FA, et al. ACCF/AHA 2010 Position Statement on Composite
40
41 Measures for Healthcare Performance Assessment: a report of the American College of
42
43 Cardiology Foundation/American Heart Association Task Force on Performance Measures
44
45 (Writing Committee to develop a position statement on composite measures). *Circulation*
46
47 2010;121:1780-91.
48
49
- 50
51 14. Shahian DM, Torchiana DF, Shemin RJ, et al. Massachusetts cardiac surgery report card:
52
53 implications of statistical methodology. *Ann Thorac Surg* 2005;80:2106-13.
54
- 55
56 15. Krumholz HM, Wang Y, Mattera JA, et al. An administrative claims model suitable for profiling
57
58
59
60

- hospital performance based on 30-day mortality rates among patients with an acute myocardial infarction. *Circulation* 2006;113:1683-92.
16. Bradley EH, Herrin J, Elbel B, et al. Hospital quality for acute myocardial infarction: correlation among process measures and relationship with short-term mortality. *JAMA* 2006;296:72-8.
17. Tung YC, Jeng JS, Chang GM, et al. Processes and outcomes of ischemic stroke care: the influence of hospital level of care. *Int J Qual Health Care* 2015;27:260-6.
18. Hsieh FI, Lien LM, Chen ST, et al. Get With the Guidelines-Stroke performance indicators: surveillance of stroke care in the Taiwan Stroke Registry: Get With the Guidelines-Stroke in Taiwan. *Circulation* 2010;122:1116-23.
19. Micieli G, Cavallini A, Quaglini S, et al. Guideline compliance improves stroke outcome: a preliminary study in 4 districts in the Italian region of Lombardia. *Stroke* 2002;33:1341-7.
20. Adelman EE, Lisabeth LD, Smith MA, et al. Stroke Performance Measures Do Not Predict Functional Outcome. *Neurohospitalist* 2017;7:113-21.
21. McNaughton H, McPherson K, Taylor W, et al. Relationship between process and outcome in stroke care. *Stroke* 2003;34:713-7.
22. Parker C, Schwamm LH, Fonarow GC, et al. Stroke quality metrics: systematic reviews of the relationships to patient-centered outcomes and impact of public reporting. *Stroke* 2012;43:155-62.
23. Salinas J, Sprinkhuizen SM, Ackerson T, et al. An International Standard Set of Patient-Centered Outcome Measures After Stroke. *Stroke* 2016;47:180-6.
24. Jauch EC, Saver JL, Adams HP, Jr., et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart

1
2
3 Association/American Stroke Association. *Stroke* 2013;44:870-947.

- 4
5
6 25. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients
7
8 with stroke and transient ischemic attack: a guideline for healthcare professionals from the
9
10 American Heart Association/American Stroke Association. *Stroke* 2014;45:2160-236.
11
12
13 26. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute
14
15 ischemic stroke. *N Engl J Med* 2008;359:1317-29.
16
17
18 27. Fonarow GC, Alberts MJ, Broderick JP, et al. Stroke outcomes measures must be appropriately
19
20 risk adjusted to ensure quality care of patients: a presidential advisory from the American
21
22 Heart Association/American Stroke Association. *Stroke* 2014;45:1589-601.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	<p>✓ Page 3 (a) Indicate the study's design with a commonly used term in the title or the abstract</p> <p>✓ Page 3 (b) Provide in the abstract an informative and balanced summary of what was done and what was found</p>
Introduction		
Background/rationale	2	✓ Page 5 Explain the scientific background and rationale for the investigation being reported
Objectives	3	✓ Page 5 State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	✓ Page 5 Present key elements of study design early in the paper
Setting	5	✓ Page 6 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	<p>✓ Page 5 (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up</p> <p>(b) For matched studies, give matching criteria and number of exposed and unexposed</p>
Variables	7	✓ Page 7-10 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	✓ Page 7-10 For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	✓ Page 21 Describe any efforts to address potential sources of bias
Study size	10	✓ Page 10 Explain how the study size was arrived at
Quantitative variables	11	✓ Page 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	<p>✓ Page 11 (a) Describe all statistical methods, including those used to control for confounding</p> <p>✓ Page 11 (b) Describe any methods used to examine subgroups and interactions</p> <p>✓ Page 11 (c) Explain how missing data were addressed</p> <p>(d) If applicable, explain how loss to follow-up was addressed</p> <p>(e) Describe any sensitivity analyses</p>
Results		
Participants	13*	<p>✓ Page 11 (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed</p> <p>✓ Page 11 (b) Give reasons for non-participation at each stage</p> <p>(c) Consider use of a flow diagram</p>
Descriptive data	14*	<p>✓ Page 11 (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders</p> <p>✓ Page 11 (b) Indicate number of participants with missing data for each variable of interest</p> <p>✓ Page 11 (c) Summarise follow-up time (eg, average and total amount)</p>
Outcome data	15*	✓ Page 16 Report numbers of outcome events or summary measures over time
Main results	16	✓ Page 17-19 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which

		confounders were adjusted for and why they were included
		✓ Page 12-15 (b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	✓ Page 16-19 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	✓ Page 20 Summarise key results with reference to study objectives
Limitations	19	✓ Page 21 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	✓ Page 20-21 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	✓ Page 21-22 Discuss the generalisability (external validity) of the study results
Other information		
Funding	22	✓ Page 23 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

Relationship between Hospital Performance Measures and Outcomes in Patients with Acute Ischemic Stroke: the China National Stroke Registry

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020467.R1
Article Type:	Research
Date Submitted by the Author:	03-Feb-2018
Complete List of Authors:	<p>Zhang, Xinmiao; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Li, Zixiao; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Zhao, Xingquan; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Xian, Ying; Department of Neurology, Duke Clinical Research Institute, Duke University,</p> <p>Liu, Liping; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Wang, Chunxue; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Wang, Chunjuan; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Li, Hao; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Prvu Bettger, J; Department of Neurology, Duke Clinical Research Institute, Duke University; Duke University School of Nursing, Duke University</p> <p>Yang, Qing; Duke University School of Nursing, Duke University</p> <p>Wang, David; INI Stroke Network, OSF Healthcare System, University of Illinois College of Medicine</p> <p>Jiang, Yong; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Bao, Xiaolei; Statistical Analysis Office, Department of Information, General Hospital of Lanzhou Military Area Command</p> <p>Yang, Xiaomeng; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Wang, Yilong; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Wang, Yongjun; Department of Neurology, Beijing Tiantan Hospital, Capital</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Medical University; China National Clinical Research Center for Neurological Diseases
Primary Subject Heading:	Neurology
Secondary Subject Heading:	Evidence based practice
Keywords:	Ischemic stroke, Quality and Outcomes, Mortality, Hospital performance

SCHOLARONE™
Manuscripts

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Title pages**

2 **Relationship between Hospital Performance Measures and Outcomes in Patients with Acute**

3 **Ischemic Stroke: the China National Stroke Registry**

4 Xinmiao Zhang^{1,2,3,4,#}, Zixiao Li^{1,2,3,4,#}, Xingquan Zhao^{1,2,3,4}, Ying Xian⁵, Liping Liu^{1,2,3,4},
5 Chunxue Wang^{1,2,3,4}, Chunjuan Wang^{1,2,3,4}, Hao Li^{1,2,3,4}, Janet Bettger^{5,6}, Qing Yang⁶, David
6 Wang⁷, Yong, Jiang^{1,2,3,4}, Xiaolei Bao⁸, Xiaomeng Yang^{1,2,3,4}, Yilong Wang^{1,2,3,4,*}, Yongjun
7 Wang^{1,2,3,4,*}; on behalf of China National Stroke Registries

8 ¹ Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

9 ² China National Clinical Research Center for Neurological Diseases, Beijing, China

10 ³ Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China

11 ⁴ Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China

12 ⁵ Department of Neurology, Duke Clinical Research Institute, Duke University, Durham, NC, USA

13 ⁶ Duke University School of Nursing, Duke University, Durham, NC, USA

14 ⁷ INI Stroke Network, OSF Healthcare System, University of Illinois College of Medicine, Peoria, IL,
15 USA

16 ⁸ Statistical Analysis Office, Department of Information, General Hospital of Lanzhou Military Area
17 Command, Lanzhou, Gansu, China

18
19 # Xinmiao Zhang and Zixiao Li contributed equally to this work.

20
21 * **Corresponding author:**

22 **Yongjun Wang: E-mail address:** yongjunwang1962@gmail.com

23 Yongjun Wang and Yilong Wang contributed equally to this paper.

1
2
3
4 1 **Key words:** Hospital performance; Ischemic stroke; Quality and Outcomes; Mortality

5
6 2 **Word count:** 3691
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1 Relationship between Hospital Performance Measures and Outcomes in Patients with Acute 2 Ischemic Stroke: the China National Stroke Registry

3 ABSTRACT

4 **Objectives:** Evidence-based performance measures were increasingly used to evaluate hospital
5 quality of stroke care, but their impact on stroke outcome has not been verified. We aimed to
6 evaluate the correlation between hospital performance measures and outcomes among acute ischemic
7 stroke patients in Chinese population.

8 **Methods:** Data was derived from 120 hospitals participating in the China National Stroke Registry
9 between September 2007 and August 2008. Adherence to 9 evidence-based performance measures
10 was examined, and the composite score of hospital performance measures was calculated. Primary
11 stroke outcomes were hospital-level, 30-day and 1-year risk-standardized mortality (RSM).
12 Association of hospital individual performance measures and composite score with stroke outcomes
13 was assessed by using Spearman correlation coefficients.

14 **Results:** The overall composite score of performance measures was 63.3%. The correlations
15 coefficients between individual performance measures ranged widely from 0.01 to 0.66. The
16 composite score was modestly associated with 1-year RSM (Spearman correlation coefficients, 0.34;
17 $P < 0.05$), however, no association was observed between the composite score and the 30-day RSM.
18 The composite score explained only 2.53% and 10.18% of hospital-level variation in 30-day and
19 1-year RSM for acute stroke patients.

20 **Conclusions:** The adherence to evidence-based performance measures for acute ischemic stroke was
21 suboptimal in China. There were various correlations among hospital individual performance

1
2
3
4 1 measures. The association of hospital performance measures with hospital-level 1-year RSM
5
6 2 mortality rates was modest.
7
8 3
9

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **1 Article summary**

4
5
6 **2 Strengths and limitations of this study:**

7
8
9 3 1. As the largest stroke database in China, hospitals participating in the China National Stroke

10
11 4 Registry encompassed different regions and had good representativeness.

12
13 5 2. We used newer risk-standardized mortality methods based on hierarchical models to account for

14
15 6 variation in case numbers across hospitals or for intra-hospital clustering effects.

16
17 7 3. Our study was observational and non-randomised. The association between hospital performance

18
19 8 measures and stroke outcomes did not necessarily prove causality.

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 INTRODUCTION

2 Stroke remains to be the leading cause of mortality in China and was responsible for \approx 1.9 million
3 deaths.¹ Although evidence-based guidelines for stroke and transient ischemic attack (TIA) care
4 have been developed and updated over time,²⁻⁴ there were variations and deficiencies in how these
5 guidelines were applied.⁵⁻⁷ To reduce the national stroke burden, several national organizations
6 developed a set of evidence-based hospital performance measures to quantify and promote the
7 quality of stroke care.⁷⁻⁹

8 Evidence-based hospital performance measures evaluated the structure, process and outcome of
9 stroke care, and provided a metric that could be tracked, reported and improved.¹⁰ Evidence-based
10 hospital performance measures were also increasingly used for certification for stroke centres,¹¹
11 public reporting¹² and remuneration for performance.¹³ Despite substantial improvement in stroke
12 care quality was observed in China, gaps in adherence to the evidence-based hospital performance
13 measures still exist. In addition, although measuring outcomes after stroke has important policy
14 implications,¹⁴ there has been limited evidence demonstrating the association between adherence to
15 performance measures and better patient outcomes.¹⁵

16 Using data from the China National Stroke Registry (CNSR), we sought to determine whether
17 evidence-based hospital performance measures were associated with short- and long-term outcomes
18 in acute ischemic stroke patients in China. Specifically, we (1) reported the hospital variation in
19 adherence to evidence-based performance measures, (2) assessed the correlation between each
20 individual performance measures, and (3) quantified the association between performance measures
21 and hospital-level, risk-standardised, 30-day and 1-year mortality among acute ischemic stroke
22 patients in China.

23 METHODS

1 CNSR overview

2 The CNSR was the first nationwide, hospital-based, prospective stroke registry of quality assessment
3 in China. It was sponsored by the Ministry of Health of the People's Republic of China to establish a
4 national stroke database for evaluating stroke care quality and outcomes, and conducted between
5 September 2007 and August 2008. The study design of CNSR has been described previously.¹⁶
6 Briefly, the criteria used for hospital selection included: (1) having at least one stroke neurologist, (2)
7 at least two sites were included from each of the 31 provinces and municipalities in mainland China,
8 (3) commitment to participate voluntarily and (4) ability to conduct research.^{16 17} The CNSR
9 recruited consecutive patients older than 18 years and diagnosed with ischemic stroke, transient
10 ischemic attack (TIA), intracerebral haemorrhage, or subarachnoid haemorrhage within 14 days of
11 the index event. We collected patients' demographics, adherence to performance measures in
12 hospitals, and status at discharge, 90-day, 6-month and 1-year follow-up after symptom onset. The
13 study was approved by the Central Institutional Review Board of Beijing Tiantan Hospital. Written
14 informed consent was acquired from the patient or legally authorised representative.

15 Data collection

16 Hospitals' characteristics were surveyed. According to annual report on health statistics of China,¹⁸
17 hospitals were divided into three regions: eastern, central and western. Academic status was defined
18 as a hospital affiliated with a specific university. Hospital bed size was the number of total inpatient
19 beds per site. Annual stroke discharge was the number of discharged patients diagnosed with stroke
20 per year per hospital.

21 Trained research coordinators at each hospital reviewed medical records daily to identify, obtain
22 informed consent, and enrol consecutive patients in accordance with the procedures indicated in a

1 standard data collection manual. The key variables in the CNSR were assessed, including: (1)
2 demographic characteristics and medical history; (2) pre-stroke modified Rankin scale (mRS), and
3 National Institutes of Health Stroke Scale (NIHSS) at admission, vascular risk factors, and clinical
4 care during hospitalization and (3) 30-day and 1-year all-cause mortality after stroke. Patients who
5 survived to discharge, or their authorised caregivers, were contacted via telephone by trained
6 research personnel who used standardised scripts for follow-up at 90 days, 6 months and 1 year after
7 stroke symptom onset¹⁶. Specific death events and dates were recorded in detail, and 30-day and
8 1-year all-cause mortality after stroke were confirmed.

9 **Performance Measures**

10 We evaluated nine hospital performance measures, including seven “core” measures for acute
11 ischemic stroke as recommended by the American Heart Association/American Stroke Association
12 (AHA/ASA) Get With The Guidelines-Stroke (GWTG-Stroke)⁷ and two additional evidence-based
13 secondary prevention metrics.⁴ These seven core performance measures included (1) intravenous
14 tissue-type plasminogen activator (tPA) in patients who arrive within 2 hours after symptom onset
15 and treated within 3 hours (IV rt-PA < 2 Hour), (2) antithrombotic medication within 48 hours of
16 admission (early antithrombotics), (3) deep vein thrombosis (DVT) prophylaxis within 48 hours of
17 admission for nonambulatory patients (DVT prophylaxis), (4) antithrombotic medication, (5)
18 anticoagulation for atrial fibrillation (AF) , (6) medications for lowering low-density lipoprotein
19 (LDL) ≥ 100 mg/dL, (7) smoking cessation. The two additional performance measures were
20 antihypertensive medication for patients with hypertension and hypoglycemia medication for
21 diabetes mellitus. Details of the performance measures were described in the Table 1.

22 Adherence to hospital-level individual performance measures was calculated as the proportion of

1 patients who received the indicated care from among all the patients who were eligible for the
 2 indicated care. The overall hospital performance measures was measured as the composite score,
 3 which was calculated by the total number of interventions actually performed among all eligible
 4 patients at a hospital, divided by the total number of recommended interventions in all eligible
 5 patients.¹⁹ Although the composite score was analysed as a continuous variable, hospitals were also
 6 divided, for descriptive purposes, into quartiles based on this continuous variable. To ensure the
 7 stability of the measure, hospitals with fewer than 20 patients in the denominator of a measure were
 8 excluded.

9 **Table 1. Specifications of evidence-based performance measures**

Performance measure of ischemic stroke care	Performance measure definition for eligible patients*
Acute performance measures	
IV rt-PA < 2 Hour	Intravenous recombinant tissue plasminogen activator (IV rtPA) in patients who arrive within 2 hours after initial symptom onset and treated within 3 hours
Early Antithrombotics	Antithrombotic therapy prescribed within 48 hours of hospitalization, including antiplatelet or anticoagulant therapy
DVT Prophylaxis	Patients at risk for deep vein thrombosis (DVT) (non-ambulatory) who received DVT prophylaxis by end of hospital day two, including pneumatic compression, warfarin sodium or heparin sodium

Performance measures at discharge

Discharge Antithrombotics	Antithrombotic therapy prescribed at discharge
Anticoagulation for Atrial Fibrillation	Anticoagulation prescribed at discharge for patients with atrial fibrillation or atrial flutter documented during the hospitalization
LDL 100	Lipid lowering agent prescribed at discharge if Low-density lipoprotein (LDL) ≥ 100 mg/dL
Antihypertension for hypertension disease:	Antihypertension medication prescribed at discharge for patients with history of hypertension disease or hypertension disease documented during the hospitalization
Hypoglycemic therapy for diabetes mellitus:	Hypoglycemic medication prescribed at discharge for patients with history of diabetes mellitus or diabetes mellitus documented during the hospitalization
Smoking Cessation	Smoking cessation intervention (counseling or medication) prior to discharge for current or recent smokers

1 * Eligible patients are those without any medical contraindications (e.g., treatment intolerance,
 2 excessive risk of adverse reaction, patient/family refusal, or terminal illness/comfort care only)
 3 documented as reasons for nontreatment for each of the applicable measures. Also excludes patients
 4 who are discharged to hospice, or another short-term general hospital, leave against medical advice
 5 before the end of hospital day two. For acute performance measures except for rt-PA measure,
 6 excludes patients who died before the end of hospital day two. The acute rt-PA measure excludes
 7 patients with missing or erroneous onset, arrival or treatment times, those who began IV t-PA at an
 8 outside hospital, or who initiated IV t-PA after 180 minutes from onset. For performance measures at

1
2
3
4 1 discharge, excludes patients who died during hospitalization. As for seven performance measures
5
6 2 from Get With The Guideline-Stroke (GWTG-Stroke), we employed the same criteria as the Get
7
8 3 With The Guideline-Stroke (GWTG-Stroke).
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Risk-standardized Mortality (RSM) Rates

2 RSM rates were calculated using a multivariate hierarchical regression model in accordance with
3 the AHA/ASA recommendations for risk adjustment of ischemic stroke outcomes to compare
4 hospital performance.¹⁵ The first level of the hierarchical model included patient characteristics.
5 These patient's variables were divided into three categories: (1) demographics and clinical features:
6 age, gender, health insurance type (urban basic medical insurance schemes for urban and
7 governmental employees and urban residents, new rural cooperative medical schemes for rural
8 residents, commercial insurance, and self-payment), transport to hospital by emergency medical
9 service, and NIHSS score at admission; (2) vascular risk factors: hypertension, diabetes mellitus,
10 dyslipidaemia, AF, coronary artery disease, previous myocardial infarction, congestive heart failure,
11 valvular heart disease, history of stroke/TIA, peripheral vascular disease, current smoking, and
12 excessive alcohol consumption; (3) other pre-existing comorbid conditions: chronic obstructive
13 pulmonary disease, hepatic cirrhosis, peptic ulcer, previous gastrointestinal bleeding, Alzheimer's
14 disease/dementia, cancer, DVT/pulmonary embolus, renal dialysis, pre-stroke dependence (mRS ≥ 3),
15 and blood glucose at admission. The second level included hospital-specific random intercepts that
16 allow for different baseline mortality rates between hospitals. The hospital RSM rates were obtained
17 as the ratio of "predicted" to expected mortality, multiplied by the unadjusted mortality rate for the
18 total population.^{20,21} The expected outcome for each hospital was the number of deaths expected at
19 the hospital if the hospital's patients were treated at a "reference" hospital. The predicted hospital
20 outcome was the number of expected mortalities at the "specific" hospital and not at a reference
21 hospital.

22 Statistical analyses

1
2
3
4 1 Numbers (percentages) were used to describe categorical variables, and median values with
5
6 2 interquartile ranges (IQRs) were reported for continuous variables. The correlations of individual
7
8 3 performance measures, as well as performance measures and stroke outcomes, were evaluated using
9
10 4 Spearman correlation coefficients. The bonferroni correction was performed in the multiple
11
12 5 comparisons. The inter-class correlation (ICC) of 30-day and 1-year RSM rate were calculated. We
13
14 6 also reported both the relevant correlation coefficients and the percentage of the hospital-specific
15
16 7 variation in RSM rates was explained; i.e., the squares of the correlation coefficients as indicators of
17
18 8 the strength of the associations.²²

19
20
21
22
23 9 All tests were two-tailed, and statistical significance was determined at the α level of 0.05 in
24
25 10 univariate and multivariate analyses. Statistical analysis was performed using SAS 9.3 (SAS Institute
26
27 11 Inc., Cary, NC, USA).

30 12 **RESULTS**

33 13 **Study hospitals and patient baseline characteristics**

34
35 14 Among 14,526 eligible patients diagnosed with acute ischemic stroke from 132 hospitals
36
37 15 throughout China, complete 1-year follow-up information was available for 12,173 patients (83.8%).
38
39 16 We excluded 12 hospitals with fewer than 20 patients in the denominator of a measure. Finally, 120
40
41 17 hospitals that recruited 12,027 patients with ischemic stroke were included in our analysis. Hospital
42
43 18 and patient baseline characteristics were described in Table 2. Among 120 hospitals, 62 (51.67%)
44
45 19 hospitals were teaching hospitals and 70 (58.33%) were from eastern regions. The median hospital
46
47 20 bed size was 1200 (IQR, 700–1861) and annual stroke volume was 430 (IQR, 310–601). Among
48
49 21 12,027 patients, 7407 (61.59%) were men, and the median age was 67 (IQR, 57–75) years. Common
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 1 vascular risk factors included hypertension, previous stroke/ TIA, smoking history, and diabetes. The
5
6 2 median NIHSS score was 4 (IQR, 2–9).

3 **Variability in performance measures**

4 The overall composite score was 63.3% among the 120 hospitals. However, the composite score
5 for each hospital varied considerably among the CNSR (Table 3). The hospitals in the highest
6 quartile (quartile 4) had a median (IQR) composite score of 85.1% (82.2%–89.9%), compared with
7 50.9% (44.2%–58.1%) for those in the lowest quartile (quartile 1).

8 In table 3, we showed hospital rates (median and IQR) for each process measure as well as 30-day
9 and 1-year RSM rates. Within acute interventions, early antithrombotics showed the lowest degree of
10 variance, although the difference between the first and third quartiles remained significant. In
11 contrast, there were twofold to threefold differences in the use of IV rt-PA < 2 Hour, DVT
12 prophylaxis, anticoagulant for AF and lipid-lowering medication for LDL \geq 100 mg/dl.

Table 2. Baseline characteristics of patients with acute ischemic stroke among China National Stroke Registry

	Level	N (%)
Patient characteristics		
Total		12 027
Demographics		
Age, yr	Median (IQR)	67 (57-75)
Gender	Male	7 407(61.59)
	Female	4 620(38.41)
Insurance scheme	UBMIS	7 311(60.79)
	NRCMS	2 027(16.85)
	Commercial	397(3.30)
	Self-payment	2 292(19.06)
Transport to hospital by EMS	Yes	1 901(15.81)
NIHSS at admission	Median (IQR)	4 (2-9)
Vascular risk factors		
Previous stroke/TIA	Yes	4 088(33.99)
Diabetes	Yes	2 593(21.56)
Hypertension	Yes	7 672(63.79)
Dyslipidemia	Yes	1 344(11.17)
CHD/previous MI	Yes	1 748(14.53)
Atrial fibrillation	Yes	892(7.42)
PVD	Yes	76(0.63)
Ever Smoking	Yes	4 779(39.74)

1			
2			
3			
4	Heavy drinking	Yes	1 873(15.57)
5			
6	Pre-existing comorbid condition		
7			
8	Congestive heart failure	Yes	250(2.08)
9			
10	Valvular Heart Disease	Yes	288(2.42)
11			
12	Chronic obstructive pulmonary	Yes	138(1.15)
13			
14	Hepatic cirrhosis	Yes	41(0.34)
15			
16	Peptic ulcer disease	Yes	336(2.81)
17			
18	Previous gastrointestinal bleeding	Yes	184(1.54)
19			
20	Dementia/Alzheimer's disease	Yes	156(1.30)
21			
22	Cancer	Yes	215(1.80)
23			
24	Deep venous thrombosis/Pulmonary	Yes	77(0.64)
25			
26	Renal Dialysis	Yes	9(0.08)
27			
28	Pre-stroke dependence (mRS>2)	Yes	1 120(9.31)
29			
30	Glucose on admission	Yes	2 328(19.72)
31			
32			
33			
34	Hospital characteristics		
35			
36	Total		120
37			
38	Hospital size		
39			
40	Beds	Median (IQR)	1 200 (700, 1 861)
41			
42	Hospital type		
43			
44	Teaching	Yes	62(51.67)
45			
46	Annual stroke discharges	Median (IQR)	430 (310,601)
47			
48	Geographic region		
49			
50	East	Yes	70 (58.33)
51			
52	Middle	Yes	26 (21.67)
53			
54			
55			
56			
57			
58			
59			
60			

West	Yes	24 (20.0)
------	-----	-----------

- 1 IQR, interquartile range; UBMIS, urban basic medical insurance scheme; NRCMS, new rural
2 cooperative medical scheme; EMS, emergency medical service; NIHSS, National Institutes of Health
3 Stroke Scale; TIA, transient ischemic attack; CHD, coronary artery disease; MI, myocardial
4 infarction; PVD, peripheral vascular disease; mRS, modified Rankin scale.

For peer review only

1 **Table 3. Hospital performance measures and RSM rates**

Measures	Median (IQR, %)
Composite score	65.65 (59.05-72.75)
Acute interventions	
IV rt-PA < 2 Hour	0.00 (0.00-25.00)
Early antithrombotics	80.68 (73.21-88.24)
DVT prophylaxis	59.22 (33.33-70.00)
Discharge interventions	
Discharge	77.00 (64.89-85.15)
antithrombotics	
Anticoagulation for AF	14.29 (0.00-26.97)
LDL 100	41.89 (25.00-61.72)
Antihypertensive	61.37 (45.46-75.00)
Medication	
Antidiabetic Medication	67.03 (53.15-79.58)
Smoking cessation	70.87 (50.55-83.33)
RSM rate	
30-day	5.41 (4.91-6.17)
1-year	13.55 (12.77-14.48)

2 IV, intravenous; rt-PA, recombinant tissue-type plasminogen; DVT, deep vein thrombosis; AF,
3 atrial fibrillation; LDL, low-density lipoprotein; RSM, risk-standardised mortality.

1 **Correlations of performance measures**

2 The correlations between two individual hospital performance measures varied widely (Table 4).
3 After bonferroni correction ($P < 0.001$), we found moderate correlation (Spearman correlation
4 coefficients ≥ 0.40 ; $P < 0.001$ for all) for all pairwise comparisons between antithrombotic at
5 discharge and lipid-lowering drugs for LDL ≥ 100 mg/dl, antihypertensive medication, and
6 antidiabetic medication; and between antidiabetic medication and antihypertensive medication and
7 smoking cessation at discharge. Other hospital performance measures had a modest correlation or no
8 correlation with each other (Spearman correlation coefficient < 0.40 for all).

9 **Association of performance measures with hospital-level RSM rates**

10 The median 30-day and 1-year RSM rate (IQR) was 5.41% (4.91%–6.17%) and 13.55%
11 (12.77%–14.48%), respectively (Table 3). The ICC of 30-day RSM rate was 0.065, and the ICC of
12 1-year RSM rate was 0.041.

13 Several performance measures showed a statistically significant, but modest, correlation with
14 1-year RSM rates, including antithrombotics at discharge (Spearman correlation coefficients= 0.32),
15 antihypertensive medication (Spearman correlation coefficients= 0.30) and antidiabetic medication
16 (Spearman correlation coefficients= 0.31) ($P < 0.05$ for all) (Table 4). No correlations were observed
17 between all performance measures and 30-day RSM rates. These performance measures individually
18 explained between 0.04% and 5.02% of hospital-level variation in 30-day RSM rates, and between
19 0.08% and 10.05% of hospital-level variation in 1-year RSM rates (Table 5).

20 The hospital-level composite score had a modest correlation with 1-year RSM rates (Spearman
21 correlation coefficients= 0.32), however, no correlation was observed between the composite score
22 and the 30-day RSM rate (Spearman correlation coefficients= 0.16). The composite score explained

-
- 1 2.53% and 10.18% of the hospital-level variation in 30-day and 1-year RSM rates, respectively
 - 2 (Table 5).

For peer review only

Table 4. Correlation coefficients for performance measures and hospital RSM rate (30-day and 1-year)

	Acute interventions			Discharge interventions						
	IV rt-PA < 2 Hour	Early antithrombotics	DVT prophylaxis	Antithrombotics	Anticoagulation for AF	Lipid-lowering drug for LDL ≥ 100 mg/dl	Antihypertensive Medication	Antidiabetic Medication	Smoking cessation	Composite score
Acute interventions										
IV rt-PA < 2 Hour	1.00									
Early antithrombotics	0.01	1.00								
DVT prophylaxis	0.08	0.23	1.00							
Discharge interventions										
Antithrombotics	0.01	0.34*	0.03	1.00						
Anticoagulation for AF	-0.01	0.04	0.19	0.16	1.00					
LDL 100	0.08	0.13	0.07	0.44*	0.26*	1.00				
Antihypertensive Medication	-0.02	0.08	-0.09	0.59*	0.12	0.27*	1.00			
Antidiabetic Medication	0.04	0.10	0.07	0.66*	0.17	0.31*	0.64*	1.00		

Smoking cessation	-0.01	0.34*	0.01	0.34*	0.25*	0.13	0.21	0.26*	1.00	
Composite score	0.05	0.48*	0.24	0.79*	0.32*	0.69*	0.60*	0.62*	0.47*	1.00
Risk-standardized 30-day mortality rate	-0.16	-0.02	-0.06	-0.16	0.04	-0.09	-0.17	-0.22	-0.04	-0.16
Risk-standardized 1-year mortality rate	-0.12	-0.03	-0.11	-0.32*	-0.07	-0.22	-0.30*	-0.31*	-0.02	-0.32*

IV, intravenous; rt-PA, recombinant tissue-type plasminogen; DVT, deep vein thrombosis; AF, atrial fibrillation; LDL, low-density

lipoprotein; RSM, risk-standardised mortality.

*P<0.001.

Table 5. Variance in 30-day and 1-year RSM rates explained by each performance measure and composite measure

Measures	30-day RSM rate	1-year RSM rate
	% variance explained	% variance explained
Acute interventions		
IV rt-PA < 2 Hour	2.43%	1.32%
Early antithrombotics	0.04%	0.08%
DVT prophylaxis	0.38%	1.14%
Discharge interventions		
Discharge antithrombotics	2.59%	10.05%
Anticoagulation for AF	0.14%	0.45%
LDL 100	0.76%	4.67%
Antihypertensive Medication	2.99%	9.24%
Antidiabetic Medication	5.02%	9.49%
Smoking cessation	0.18%	0.06%
Composite score	2.53%	10.18%

IV, intravenous; rt-PA, recombinant tissue-type plasminogen; DVT, deep vein thrombosis; AF, atrial fibrillation; LDL, low-density lipoprotein; RSM, risk-standardised mortality.

1 DISCUSSION

2 The present study found that ischemic stroke care was suboptimal in China and there were various
3 correlations among hospital performance measures. The hospital-level composite score had a modest
4 correlation with 1-year RSM rate, however, no correlation was observed between the composite
5 score and 30-day RSM rate. This finding suggested hospital performance measures cannot reliably
6 infer short- and long- term mortality rates after acute ischemic stroke. Our results underscored that
7 the current performance measures of stroke care provided complementary, but not redundant,
8 information with the measures of 30-day and 1-year mortality.

9 When compared our data with the GWTG-Stroke in America, we found that ischemic stroke care
10 was suboptimal in China. The GWTG-Stroke program was developed by the AHA/ASA as a national
11 stroke registry and performance improvement program with the primary goal of improving the
12 quality of care and outcomes for stroke and TIA in America.^{7 14} The comparison showed that many
13 hospital performance measures in China were far down from the GWTG-Stroke,^{14 23} including the
14 composite score (63.3% in 2007 CNSR versus 94.0% in 2007 GWTG-Stroke), IV rt-PA < 2 Hour
15 (14.1% in 2007 CNSR versus 72.8% in 2007 GWTG-Stroke), early antithrombotics (80.3% in 2007
16 CNSR versus 97.0% in 2007 GWTG-Stroke), DVT Prophylaxis (59.6% in 2007 CNSR versus 89.5%
17 in 2007 GWTG-Stroke), discharge antithrombotics (71.0% in 2012 CNSR versus 98.9% in 2007
18 GWTG-Stroke), anticoagulation for atrial fibrillation (19.7% in 2007 CNSR versus 98.4% in 2007
19 GWTG-Stroke), lipid-lowering drug for low-density lipoprotein ≥ 100 mg/dL (42.6% in 2012
20 CNSR versus 88.3% in 2007 GWTG-Stroke), and smoking cessation (63.3% in 2007 CNSR versus
21 93.6% in 2007 GWTG-Stroke). Financial burden, lacking of stroke center certification and stroke
22 education might become the main reasons.

1 The relationship between performance measures and stroke outcomes still exists uncertainty. Some
2 studies have indicated the use of performance measures was associated with lower short-term
3 mortality or better functional outcomes.²⁴⁻²⁶ However, the link between stroke performance measures
4 and outcome was not straightforward in certain other studies.²⁷⁻³⁰ There were several probable
5 reasons for the modest correlation between hospital-level performance measures and
6 risk-standardised mortality in the present study. First, although clinical trials have shown a
7 significant relationship between process interventions and outcomes,^{31 32} the evidence-based
8 performance measures were not mainly designed to be a substitute for overall short- and long-term
9 hospital mortality. Second, there was relative little variation across hospitals in some performance
10 measures, such as early antithrombotics after admission, which limited the ability to discriminate
11 between hospitals based on their performance on this measure. Additionally, some performance
12 measures, such as intravenous thrombolysis, may had a greater effect regarding stroke-related
13 disability than that in stroke-related mortality.³³ Finally, hospital mortality rates, even
14 risk-standardised ones, were likely affected by many factors independent of the performance
15 measures of stroke care quality. These included severity of stroke, patients' or their family's
16 preference, economic level and clinical strategies that may contribute to a hospital's performance
17 outcomes.³⁴

18 The present study also demonstrated a significant correlation between certain evidence-based
19 performance measures for acute ischemic stroke care, indicating the hospitals that perform well in
20 one performance measure were likely to perform well in the others. However, other performance
21 measures were less strongly correlated with each other. This finding implies different performance
22 measures reflect separate components of quality in acute ischemic stroke care. Our work indicated

1 that hospital performance rankings were likely to be substantially affected by the performance
2 measures under selection. A broad range of performance measures appears necessary to
3 comprehensively reflect hospital care practices.

4 Our study had several strengths. First, to date, the CNSR was the largest stroke database in China.
5 Hospitals participating in the CNSR encompassed different regions and had good representativeness.
6 Second, we used newer RSM methods based on hierarchical models to account for variation in case
7 numbers across hospitals or for intra-hospital clustering effects.¹⁵ Third, baseline characteristics of
8 patients, such as age, gender, vascular risk factors, comorbid conditions, and stroke severity (NIHSS)
9 were adjusted in calculating the RSM in accordance with the American Heart Association/American
10 Stroke Association (AHA/ASA).^{15 34} Additionally, besides short-term RSM, our study also analysed
11 long-term RSM.

12 However, our study also had some limitations. Firstly, our study was observational and
13 non-randomised. The association between care processes and stroke outcomes did not necessarily
14 prove causality and may be confounded by previously discussed factors. Secondly, our outcome was
15 mortality; other outcomes, such as stroke recurrence and functional outcomes, were also vital to
16 patients and should be assessed in future studies.³⁰ Thirdly, the hospital performance measures,
17 stroke outcomes, and the link between them might vary over time (such as prolonged time frame to
18 perform thrombolysis). Future research need to determine the stability of the process-outcome
19 relationship as quality improvement efforts drive broader care adoption. Forthly, our data was
20 collected between 2007 and 2008, therefore the interpretation of our data might be limited. Future
21 research was needed to confirm our results. Finally, there were several differences between stroke

1 healthcare delivery systems in China and in other countries. The results reported herein came from
2 the Chinese healthcare system and therefore may not necessarily be generalisable to other countries.

3 **CONCLUSIONS**

4 The quality of process care for ischemic stroke was suboptimal in China, and there were various
5 correlations in hospital performance among the individual metrics. Although the evidence-based
6 performance measures were important in pursuing improved acute ischemic stroke outcomes, the
7 relationship between performance measures and hospital long-term risk-adjusted mortality rates was
8 modest. Much broader measures were needed to be used as a means of assessing and helping
9 improve the quality of hospital-level stroke care.

1 **Acknowledgements**

2 We thank all participating hospitals, colleagues, nurses, imaging and laboratory technicians, and
3 the CNSR Steering Committee members.

4 **Contributorship Statement**

5 XMZ and ZXL analyzed the data and wrote the manuscript. XLB, LPL, CXW, HL, JB, QY and
6 DW analyzed and interpreted the data. ZXL, CJW, YJ, XMY and XMZ performed research. YJW,
7 YLW, ZXL, YX and XQZ conceived, designed and supervised the study.

8 **Funding**

9 Supported by grants from the Ministry of Science and Technology of the People's Republic of
10 China (2006BA101A11, 2008ZX09312-008, 2011BAI08B01, 2011BAI08B02, 2012ZX09303,
11 2013BAI09B14, 2013BAI09B03, 2015BAI12B02, 2015BAI12B04, 2017YFC1310900 and
12 2017YFC1310901), grants from the Beijing Municipal Science and Technology Commission
13 (D15110700200000, D151100002015001, D151100002015002, Z161100000516223 and
14 Z141107002514125), and the Beijing Tiantan Hospital Seeding Initiative.

15 **Competing interests**

16 None.

17 **Ethics approval**

18 Approval was obtained from the Central Institutional Review Board at Beijing Tiantan Hospital.

19 **Provenance and peer review**

20 Not commissioned; externally peer reviewed.

21 **Data sharing statement:** No additional data are available.

1 References

- 1 1. Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990-2013:
2 a systematic subnational analysis for the Global Burden of Disease Study 2013. *Lancet*
3 2016;387:251-72.
- 4 2. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic
5 stroke or transient ischemic attack: a statement for healthcare professionals from the
6 American Heart Association/American Stroke Association Council on Stroke: co-sponsored
7 by the Council on Cardiovascular Radiology and Intervention: the American Academy of
8 Neurology affirms the value of this guideline. *Stroke* 2006;37:577-617.
- 9 3. Adams HP, Jr., del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with
10 ischemic stroke: a guideline from the American Heart Association/American Stroke
11 Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and
12 Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of
13 Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of
14 Neurology affirms the value of this guideline as an educational tool for neurologists.
15 *Circulation* 2007;115:e478-534.
- 16 4. Wang YJ, Zhang SM, Zhang L, et al. Chinese guidelines for the secondary prevention of ischemic
17 stroke and transient ischemic attack 2010. *CNS Neurosci Ther* 2012;18:93-101.
- 18 5. Reeves MJ, Arora S, Broderick JP, et al. Acute stroke care in the US: results from 4 pilot
19 prototypes of the Paul Coverdell National Acute Stroke Registry. *Stroke* 2005;36:1232-40.
- 20 6. Hinchey JA, Shephard T, Tonn ST, et al. Benchmarks and determinants of adherence to stroke
21 performance measures. *Stroke* 2008;39:1619-20.

- 1 7. Fonarow GC, Reeves MJ, Smith EE, et al. Characteristics, performance measures, and in-hospital
2 outcomes of the first one million stroke and transient ischemic attack admissions in get with
3 the guidelines-stroke. *Circ Cardiovasc Qual Outcomes* 2010;3:291-302.
- 4 8. LaBresh KA, Reeves MJ, Frankel MR, et al. Hospital treatment of patients with ischemic stroke or
5 transient ischemic attack using the "Get With The Guidelines" program. *Arch Intern Med*
6 2008;168:411-7.
- 7 9. Ellrodt AG, Fonarow GC, Schwamm LH, et al. Synthesizing lessons learned from get with the
8 guidelines: the value of disease-based registries in improving quality and outcomes.
9 *Circulation* 2013;128:2447-60.
- 10 10. Measuring and improving quality of care: a report from the American Heart
11 Association/American College of Cardiology First Scientific Forum on Assessment of
12 Healthcare Quality in Cardiovascular Disease and Stroke. *Circulation* 2000;101:1483-93.
- 13 11. Alberts MJ, Latchaw RE, Jagoda A, et al. Revised and updated recommendations for the
14 establishment of primary stroke centers: a summary statement from the brain attack coalition.
15 *Stroke* 2011;42:2651-65.
- 16 12. Krumholz HM, Keenan PS, Brush JE, Jr., et al. Standards for measures used for public reporting
17 of efficiency in health care: a scientific statement from the American Heart Association
18 Interdisciplinary Council on Quality of Care and Outcomes Research and the American
19 College of Cardiology Foundation. *Circulation* 2008;118:1885-93.
- 20 13. Lindenauer PK, Remus D, Roman S, et al. Public reporting and pay for performance in hospital
21 quality improvement. *N Engl J Med* 2007;356:486-96.
- 22 14. Schwamm LH, Fonarow GC, Reeves MJ, et al. Get With the Guidelines-Stroke is associated with

- 1 sustained improvement in care for patients hospitalized with acute stroke or transient
2 ischemic attack. *Circulation* 2009;119:107-15.
- 3 15. Katzan IL, Spertus J, Bettger JP, et al. Risk adjustment of ischemic stroke outcomes for
4 comparing hospital performance: a statement for healthcare professionals from the American
5 Heart Association/American Stroke Association. *Stroke* 2014;45:918-44.
- 6 16. Wang Y, Cui L, Ji X, et al. The China National Stroke Registry for patients with acute
7 cerebrovascular events: design, rationale, and baseline patient characteristics. *Int J Stroke*
8 2011;6:355-61.
- 9 17. Wang Y, Liao X, Zhao X, et al. Using recombinant tissue plasminogen activator to treat acute
10 ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry
11 (CNSR). *Stroke* 2011;42:1658-64.
- 12 18. Ministry of health of the people's republic of china . Annual report on health statistics of china
13 2010 [in chinese] . Beijing, china : Publishing house of the peking union medical college ;
14 2010.
- 15 19. Peterson ED, DeLong ER, Masoudi FA, et al. ACCF/AHA 2010 Position Statement on Composite
16 Measures for Healthcare Performance Assessment: a report of the American College of
17 Cardiology Foundation/American Heart Association Task Force on Performance Measures
18 (Writing Committee to develop a position statement on composite measures). *Circulation*
19 2010;121:1780-91.
- 20 20. Shahian DM, Torchiana DF, Shemin RJ, et al. Massachusetts cardiac surgery report card:
21 implications of statistical methodology. *Ann Thorac Surg* 2005;80:2106-13.
- 22 21. Krumholz HM, Wang Y, Mattera JA, et al. An administrative claims model suitable for profiling

- 1 hospital performance based on 30-day mortality rates among patients with an acute
2 myocardial infarction. *Circulation* 2006;113:1683-92.
- 3 22. Bradley EH, Herrin J, Elbel B, et al. Hospital quality for acute myocardial infarction: correlation
4 among process measures and relationship with short-term mortality. *JAMA* 2006;296:72-8.
- 5 23. Li Z, Wang C, Zhao X, et al. Substantial Progress Yet Significant Opportunity for Improvement
6 in Stroke Care in China. *Stroke* 2016;47:2843-49.
- 7 24. Tung YC, Jeng JS, Chang GM, et al. Processes and outcomes of ischemic stroke care: the
8 influence of hospital level of care. *Int J Qual Health Care* 2015;27:260-6.
- 9 25. Hsieh FI, Lien LM, Chen ST, et al. Get With the Guidelines-Stroke performance indicators:
10 surveillance of stroke care in the Taiwan Stroke Registry: Get With the Guidelines-Stroke in
11 Taiwan. *Circulation* 2010;122:1116-23.
- 12 26. Micieli G, Cavallini A, Quaglini S, et al. Guideline compliance improves stroke outcome: a
13 preliminary study in 4 districts in the Italian region of Lombardia. *Stroke* 2002;33:1341-7.
- 14 27. Adelman EE, Lisabeth LD, Smith MA, et al. Stroke Performance Measures Do Not Predict
15 Functional Outcome. *Neurohospitalist* 2017;7:113-21.
- 16 28. McNaughton H, McPherson K, Taylor W, et al. Relationship between process and outcome in
17 stroke care. *Stroke* 2003;34:713-7.
- 18 29. Parker C, Schwamm LH, Fonarow GC, et al. Stroke quality metrics: systematic reviews of the
19 relationships to patient-centered outcomes and impact of public reporting. *Stroke*
20 2012;43:155-62.
- 21 30. Salinas J, Sprinkhuizen SM, Ackerson T, et al. An International Standard Set of Patient-Centered
22 Outcome Measures After Stroke. *Stroke* 2016;47:180-6.

-
- 1 31. Jauch EC, Saver JL, Adams HP, Jr., et al. Guidelines for the early management of patients with
2 acute ischemic stroke: a guideline for healthcare professionals from the American Heart
3 Association/American Stroke Association. *Stroke* 2013;44:870-947.
- 4 32. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients
5 with stroke and transient ischemic attack: a guideline for healthcare professionals from the
6 American Heart Association/American Stroke Association. *Stroke* 2014;45:2160-236.
- 7 33. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute
8 ischemic stroke. *N Engl J Med* 2008;359:1317-29.
- 9 34. Fonarow GC, Alberts MJ, Broderick JP, et al. Stroke outcomes measures must be appropriately
10 risk adjusted to ensure quality care of patients: a presidential advisory from the American Heart
11 Association/American Stroke Association. *Stroke* 2014;45:1589-601.

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	✓ Page 3 (a) Indicate the study's design with a commonly used term in the title or the abstract
		✓ Page 3 (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2	✓ Page 5 Explain the scientific background and rationale for the investigation being reported
Objectives	3	✓ Page 5 State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	✓ Page 5 Present key elements of study design early in the paper
Setting	5	✓ Page 6 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	✓ Page 5 (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	7	✓ Page 7-10 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	✓ Page 7-10 For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	✓ Page 21 Describe any efforts to address potential sources of bias
Study size	10	✓ Page 10 Explain how the study size was arrived at
Quantitative variables	11	✓ Page 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	✓ Page 11 (a) Describe all statistical methods, including those used to control for confounding ✓ Page 11 (b) Describe any methods used to examine subgroups and interactions ✓ Page 11 (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses
Results		
Participants	13*	✓ Page 11 (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed ✓ Page 11 (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	✓ Page 11 (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders ✓ Page 11 (b) Indicate number of participants with missing data for each variable of interest ✓ Page 11 (c) Summarise follow-up time (eg, average and total amount)
Outcome data	15*	✓ Page 16 Report numbers of outcome events or summary measures over time
Main results	16	✓ Page 17-19 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which

		confounders were adjusted for and why they were included
		✓ Page 12-15 (b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	✓ Page 16-19 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	✓ Page 20 Summarise key results with reference to study objectives
Limitations	19	✓ Page 21 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	✓ Page 20-21 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	✓ Page 21-22 Discuss the generalisability (external validity) of the study results
Other information		
Funding	22	✓ Page 23 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

Relationship between Hospital Performance Measures and Outcomes in Patients with Acute Ischemic Stroke: a Prospective Cohort Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020467.R2
Article Type:	Research
Date Submitted by the Author:	13-Mar-2018
Complete List of Authors:	<p>Zhang, Xinmiao; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Li, Zixiao; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Zhao, Xingquan; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Xian, Ying; Department of Neurology, Duke Clinical Research Institute, Duke University,</p> <p>Liu, Liping; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Wang, Chunxue; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Wang, Chunjuan; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Li, Hao; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Prvu Bettger, J; Department of Neurology, Duke Clinical Research Institute, Duke University; Duke University School of Nursing, Duke University</p> <p>Yang, Qing; Duke University School of Nursing, Duke University</p> <p>Wang, David; INI Stroke Network, OSF Healthcare System, University of Illinois College of Medicine</p> <p>Jiang, Yong; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Bao, Xiaolei; Statistical Analysis Office, Department of Information, General Hospital of Lanzhou Military Area Command</p> <p>Yang, Xiaomeng; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Wang, Yilong; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Wang, Yongjun; Department of Neurology, Beijing Tiantan Hospital, Capital</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Medical University; China National Clinical Research Center for Neurological Diseases
Primary Subject Heading:	Neurology
Secondary Subject Heading:	Evidence based practice
Keywords:	Hospital performance, Ischemic stroke, Quality and outcomes, Mortality

SCHOLARONE™
Manuscripts

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2017-020467 on 1 August 2018. Downloaded from <http://bmjopen.bmj.com/> on April 20, 2024 by guest. Protected by copyright.

1 **Title pages**

2 **Relationship between Hospital Performance Measures and Outcomes in Patients with Acute**
3 **Ischemic Stroke: a Prospective Cohort Study**

4 Xinmiao Zhang^{1,2,3,4,#}, Zixiao Li^{1,2,3,4,#}, Xingquan Zhao^{1,2,3,4}, Ying Xian⁵, Liping Liu^{1,2,3,4},
5 Chunxue Wang^{1,2,3,4}, Chunjuan Wang^{1,2,3,4}, Hao Li^{1,2,3,4}, Janet Bettger^{5,6}, Qing Yang⁶, David
6 Wang⁷, Yong, Jiang^{1,2,3,4}, Xiaolei Bao⁸, Xiaomeng Yang^{1,2,3,4}, Yilong Wang^{1,2,3,4,*}, Yongjun
7 Wang^{1,2,3,4,*}; on behalf of China National Stroke Registries

8 ¹ Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

9 ² China National Clinical Research Center for Neurological Diseases, Beijing, China

10 ³ Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China

11 ⁴ Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China

12 ⁵ Department of Neurology, Duke Clinical Research Institute, Duke University, Durham, NC, USA

13 ⁶ Duke University School of Nursing, Duke University, Durham, NC, USA

14 ⁷ INI Stroke Network, OSF Healthcare System, University of Illinois College of Medicine, Peoria, IL,
15 USA

16 ⁸ Statistical Analysis Office, Department of Information, General Hospital of Lanzhou Military Area
17 Command, Lanzhou, Gansu, China

18
19 # Xinmiao Zhang and Zixiao Li contributed equally to this work.

20
21 * **Corresponding author:**

22 **Yongjun Wang: E-mail address:** yongjunwang1962@gmail.com

23 Yongjun Wang and Yilong Wang contributed equally to this paper.

24

1
2
3
4 1 **Key words:** Hospital performance; Ischemic stroke; Quality and outcomes; Mortality

5
6 2 **Word count:** 3764
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1 **Relationship between Hospital Performance Measures and Outcomes in Patients with Acute**
2
3
4 **Ischemic Stroke: a Prospective Cohort Study**
5
6

7
8 **ABSTRACT**
9

10 **Objectives:** Evidence-based performance measures were increasingly used to evaluate the hospital
11
12 quality of stroke care, but their impact on stroke outcomes has not been verified. We aimed to
13
14 evaluate the correlations between hospital performance measures and outcomes among acute
15
16 ischemic stroke patients in Chinese population.
17
18

19 **Methods:** Data was derived from a prospective cohort, which included 120 hospitals participating in
20
21 the China National Stroke Registry between September 2007 and August 2008. Adherence to
22
23 evidence-based performance measures was examined, and the composite score of hospital
24
25 performance measures was calculated. Primary stroke outcomes were hospital-level, 30-day and
26
27 1-year risk-standardized mortality (RSM). Associations of individual performance measures and
28
29 composite score with stroke outcomes were assessed by using Spearman correlation coefficients.
30
31

32 **Results:** One hundred and twenty hospitals that recruited 12,027 patients with ischemic stroke were
33
34 included in our analysis. Among 12,027 patients, 61.59% were men, and the median age was 67
35
36 years. The overall composite score of performance measures was 63.3%. The correlation coefficients
37
38 between individual performance measures ranged widely from 0.01 to 0.66. No association was
39
40 observed between the composite score and 30-day RSM. The composite score was modestly
41
42 associated with 1-year RSM (Spearman correlation coefficients, 0.34; $P < 0.05$). The composite score
43
44 explained only 2.53% and 10.18% of hospital-level variation in 30-day and 1-year RSMs for acute
45
46 stroke patients.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 1 **Conclusions:** The adherence to evidence-based performance measures for acute ischemic stroke was
5
6 2 suboptimal in China. There were various correlations among hospital individual performance
7
8 3 measures. The hospital performance measures had no correlations with 30-day RSM rate and modest
9
10
11 4 correlations with 1-year RSM rate.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 1 **Article summary**

5
6 2 **Strengths and limitations of this study:**

7
8 3 1. As the largest stroke database in China, hospitals participating in the China National Stroke

9
10
11 4 Registry encompassed different regions and had good representativeness.

12
13 5 2. We used the newer risk-standardized mortality method based on hierarchical models to account for

14
15 6 variation in case numbers across hospitals or for intra-hospital clustering effects.

16
17
18 7 3. Our study was observational and non-randomised. The association between hospital performance

19
20
21 8 measures and stroke outcomes did not necessarily prove causality.

22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 9

1 INTRODUCTION

2 Stroke remains to be the leading cause of mortality in China and was responsible for around 1.9
3 million deaths in 2013.¹ Although evidence-based guidelines for stroke and transient ischemic
4 attack (TIA) have been developed and updated over time,²⁻⁴ there were variations and deficiencies
5 in how these guidelines were applied.⁵⁻⁷ To reduce the national stroke burden, several national
6 organizations have developed a set of evidence-based hospital performance measures to quantify
7 and promote the quality of stroke care.⁷⁻⁹

8 Evidence-based hospital performance measures evaluated the structure, process and outcome of
9 stroke care, and provided a metric that could be tracked, reported and improved.¹⁰ Evidence-based
10 hospital performance measures were also increasingly used for certification of stroke centres,¹¹
11 public reporting¹² and remuneration for performance.¹³ Although there has been substantial
12 improvement in stroke care quality in China, gaps still exist in adherence to the evidence-based
13 hospital performance measures. In addition, although measuring outcomes after stroke has important
14 policy implications,¹⁴ there has been limited evidence demonstrating the association between
15 adherence to performance measures and better patient outcomes.¹⁵

16 The China National Stroke Registry (CNSR) was a national hospital-based, prospective stroke
17 registry, which encompassed different regions and had good representativeness.¹⁶ CNSR thoroughly
18 investigated all indicators related to the quality of stroke care, including evidence-based acute
19 performance measures and performance measures at discharge. Thus, it could reflect the real
20 situation of stroke care in China. Using data from the CNSR, we sought to determine whether
21 evidence-based hospital performance measures were associated with short- and long-term outcomes
22 in acute ischemic stroke patients in China. Specifically, we (1) reported the hospital variations in
23 adherence to evidence-based performance measures, (2) assessed the correlations between each

1 individual performance measures, and (3) quantified the associations between the performance
2 measures and hospital-level, risk-standardised, 30-day and 1-year mortalities among acute ischemic
3 stroke patients in China.

4 **METHODS**

5 **CNSR overview**

6 The CNSR was the first nationwide, hospital-based, prospective stroke registry of quality assessment
7 in China, which conducted between September 2007 and August 2008. It was sponsored by the
8 Ministry of Health of the People's Republic of China to establish a national stroke database to
9 evaluate the stroke care quality and outcomes. The study design of CNSR has been described
10 previously.¹⁶ Briefly, the criteria used for hospital selection included: (1) having at least one stroke
11 neurologist, (2) at least two sites were included from each of the 31 provinces and municipalities in
12 mainland China, (3) commitment to participate voluntarily and (4) ability to conduct research.^{16 17}

13 The CNSR recruited consecutive patients older than 18 years and diagnosed with ischemic stroke,
14 TIA, intracerebral haemorrhage, or subarachnoid haemorrhage within 14 days of the index event. We
15 collected patients' demographics, adherence to performance measures during hospitalization, and
16 status at discharge, 90-day, 6-month and 1-year follow-up after symptom onset. The study was
17 approved by the Central Institutional Review Board of Beijing Tiantan Hospital. Written informed
18 consent was acquired from the patient or the legally authorised representative.

19 **Data collection**

20 Hospitals' characteristics were surveyed. According to annual report on health statistics of China,¹⁸
21 hospitals were divided into three regions: eastern, central and western. Academic status was defined
22 as being affiliated with a specific university or not. Hospital bed size was the number of total

1 inpatient beds per site. Annual stroke discharge was the number of discharged patients diagnosed
2 with stroke per year of each participating hospital.

3 Trained research coordinators at each hospital reviewed medical records daily to identify, obtain
4 informed consent, and enrol consecutive patients in accordance with the procedures indicated in a
5 standard data collection manual. The key variables in the CNSR were assessed, including: (1)
6 demographic characteristics and medical history; (2) pre-stroke modified Rankin scale (mRS) and
7 National Institutes of Health Stroke Scale (NIHSS) at admission, vascular risk factors, and clinical
8 care during hospitalization; and (3) 30-day and 1-year all-cause mortalities after stroke. Patients or
9 their authorised caregivers were contacted via telephone by trained research personnel with
10 standardised scripts for follow-up at 90 days, 6 months and 1 year after stroke symptom onset.¹⁶
11 Specific death events and dates were recorded in detail, and 30-day and 1-year all-cause mortalities
12 after stroke were confirmed.

13 **Performance Measures**

14 We evaluated nine hospital performance measures, including seven “core” measures for acute
15 ischemic stroke as recommended by the American Heart Association/American Stroke Association
16 (AHA/ASA) Get With The Guidelines-Stroke (GWTG-Stroke)⁷ and two additional evidence-based
17 secondary prevention metrics.⁴ These seven core performance measures included (1) intravenous
18 tissue-type plasminogen activator (tPA) in patients who arrived within 2 hours after symptom onset
19 and treated within 3 hours (IV rt-PA < 2 hour), (2) antithrombotic medication within 48 hours of
20 admission (early antithrombotics), (3) deep vein thrombosis (DVT) prophylaxis within 48 hours of
21 admission for nonambulatory patients (DVT prophylaxis), (4) antithrombotic medication, (5)
22 anticoagulation for atrial fibrillation (AF) , (6) medications for lowering low-density lipoprotein

1 (LDL) ≥ 100 mg/dL, (7) smoking cessation. The two additional performance measures were
2 antihypertensive medication for patients with hypertension and hypoglycemia medication for
3 diabetes mellitus. Details of the performance measures were described in Table 1.

4 Adherence to hospital-level individual performance measures was calculated as the proportion of
5 patients who received the indicated care among all the patients who were eligible for the indicated
6 care. The overall hospital performance measures were measured as the composite score, which was
7 calculated by the total number of interventions actually performed among all eligible patients at a
8 hospital, divided by the total number of recommended interventions in all eligible patients.¹⁹
9 Although the composite score was analysed as a continuous variable, hospitals were also divided, for
10 descriptive purposes, into quartiles based on this continuous variable. To ensure the stability of the
11 measure, hospitals with fewer than 20 patients in the denominator of any measures were excluded.

1 **Table 1. Specifications of evidence-based performance measures**

Performance measures of ischemic stroke care	Definition of performance measures for eligible patients*
Acute performance measures	
IV rt-PA < 2 hour	Intravenous recombinant tissue plasminogen activator (IV rtPA) in patients who arrived within 2 hours after initial symptom onset and treated within 3 hours
Early antithrombotics	Antithrombotic therapy prescribed within 48 hours of hospitalization, including antiplatelet or anticoagulant therapy
DVT prophylaxis	Patients at risk for deep vein thrombosis (DVT) (non-ambulatory) who received DVT prophylaxis by end of hospital day two, including pneumatic compression, warfarin sodium or heparin sodium
Performance measures at discharge	
Discharge antithrombotics	Antithrombotic therapy prescribed at discharge
Anticoagulation for atrial fibrillation	Anticoagulation prescribed at discharge for patients with atrial fibrillation or atrial flutter documented during hospitalization
LDL 100	Lipid lowering agent prescribed at discharge if low-density lipoprotein (LDL) ≥ 100 mg/dL
Antihypertensive therapy for hypertension	Antihypertension medication prescribed at discharge for patients with a history of hypertension or hypertension documented during hospitalization

Hypoglycemic therapy for diabetes mellitus	Hypoglycemic medication prescribed at discharge for patients with a history of diabetes mellitus or diabetes mellitus documented during hospitalization
Smoking cessation	Smoking cessation intervention (counseling or medication) prior to discharge for current or recent smokers

* Eligible patients were those without any medical contraindications (e.g., treatment intolerance, excessive risk of adverse reaction, patient/family refusal, or terminal illness/comfort care only) and documented as reasons for nontreatment for each of the applicable measures. We also excluded patients who were discharged to hospice, or another short-term general hospital, or against medical advice before the end of hospital day two. For acute performance measures except for rt-PA measure, we excluded patients who died before the end of hospital day two. For the acute rt-PA measure, we excluded patients with missing or erroneous onset, arrival or treatment times, those who began IV t-PA at an outside hospital, or who initiated IV t-PA after 180 minutes from onset. For performance measures at discharge, we excluded patients who died during hospitalization. As for seven performance measures from the Get With The Guideline-Stroke (GWTG-Stroke), we employed the same criteria as the Get With The Guideline-Stroke (GWTG-Stroke).

1 **Risk-standardized Mortality (RSM) Rates**

2 RSM rates were calculated using a multivariate hierarchical regression model in accordance with
3 the AHA/ASA recommendations for risk adjustment of ischemic stroke outcomes to compare
4 hospital performance.¹⁵ The first level of the hierarchical model included patient characteristics.
5 These patient's variables were divided into three categories: (1) demographics and clinical features:
6 age, gender, health insurance type (urban basic medical insurance schemes for urban and
7 governmental employees and urban residents, new rural cooperative medical schemes for rural
8 residents, commercial insurance, and self-payment), transport to hospital by emergency medical
9 service, and NIHSS score at admission; (2) vascular risk factors: hypertension, diabetes mellitus,
10 dyslipidaemia, AF, coronary artery disease, previous myocardial infarction, congestive heart failure,
11 valvular heart disease, history of stroke/TIA, peripheral vascular disease, current smoking, and
12 excessive alcohol consumption; (3) other pre-existing comorbid conditions: chronic obstructive
13 pulmonary disease, hepatic cirrhosis, peptic ulcer, previous gastrointestinal bleeding, Alzheimer's
14 disease/dementia, cancer, DVT/pulmonary embolus, renal dialysis, pre-stroke dependence (mRS ≥ 3),
15 and blood glucose at admission. The second level included hospital-specific random intercepts that
16 allow for different baseline mortalities between hospitals. The hospital RSM rates were obtained as
17 the ratio of "predicted" to expected mortality, multiplied by the unadjusted mortalities for the total
18 population.^{20 21} The expected outcome for each hospital was the number of deaths expected at the
19 hospital if the hospital's patients were treated at a "reference" hospital. The predicted hospital-level
20 outcome was the number of expected mortalities at the "specific" hospital and not at a reference
21 hospital.

22 **Statistical analyses**

1
2
3
4 1 Numbers (percentages) were used to describe categorical variables, and median values with
5
6 2 interquartile ranges (IQRs) were reported for continuous variables. The correlations of individual
7
8 3 performance measures, as well as performance measures and stroke outcomes, were evaluated using
9
10 4 Spearman correlation coefficients. The bonferroni correction was performed in the multiple
11
12 5 comparisons. The inter-class correlation (ICC) of 30-day and 1-year RSM rates were calculated. The
13
14 6 relevant correlation coefficients and the percentage of the hospital-specific variations in RSM rates
15
16 7 were explained using the squares of the correlation coefficients as indicators of the strength of the
17
18 8 associations.²²

19
20
21
22
23 9 All tests were two-tailed, and statistical significance was determined at the α level of 0.05 in
24
25 10 univariate and multivariate analyses. Statistical analysis was performed using SAS 9.3 (SAS Institute
26
27 11 Inc., Cary, NC, USA).

28 29 30 12 **Patient and Public Involvement**

31
32
33 13 Stroke remains to be the leading cause of mortality in China,¹ which seriously affects the quality
34
35 14 of patients' lives and brings huge burden to them. A number of national guidelines were bought out
36
37 15 to improve the quality of stroke care and to reduce stroke mortality.⁷⁻⁹ By exploring the association
38
39 16 of hospital performance measures to improve stroke care with all-cause mortality, we hope to figure
40
41 17 out whether improving stroke care quality could affect patients' mortality and improve patients'
42
43 18 prognosis.

44
45
46
47 19 The CNSR recruited consecutive patients older than 18 years and diagnosed with ischemic stroke
48
49 20 within 14 days of stroke onset from 132 hospitals throughout China between September 2007 and
50
51 21 August 2008. The results of our study would be disseminated through the follow-ups of patients in
52
53 22 CNSR, and through one of our projects of the national education of cerebrovascular diseases.

1 RESULTS

2 Study hospitals and patient baseline characteristics

3 Among 14,526 eligible patients diagnosed with acute ischemic stroke from 132 hospitals
4 throughout China, complete 1-year follow-up information was available for 12,173 patients (83.8%).

5 We excluded 12 hospitals with fewer than 20 patients in the denominator of any measures. Finally,

6 120 hospitals that recruited 12,027 patients with ischemic stroke were included in our analysis.

7 Hospital and patient baseline characteristics were described in Table 2. Among 120 hospitals, 62
8 (51.67%) hospitals were teaching hospitals and 70 (58.33%) were from eastern regions. The median
9 hospital bed size was 1200 (IQR, 700–1861) and annual stroke volume was 430 (IQR, 310–601).

10 Among 12,027 patients, 7,407 (61.59%) were men, and the median age was 67 (IQR, 57–75) years.

11 Common vascular risk factors included hypertension, previous stroke/ TIA, smoking history, and
12 diabetes. The median NIHSS score was 4 (IQR, 2–9).

13 Variability in performance measures

14 The overall composite score was 63.3% among the 120 hospitals. However, the composite score
15 for each hospital varied considerably among the CNSR (Table 3). The hospitals in the highest
16 quartile (quartile 4) had a median (IQR) composite score of 85.1% (82.2%–89.9%), compared with
17 50.9% (44.2%–58.1%) for those in the lowest quartile (quartile 1).

18 In table 3, we showed hospital rates (median and IQR) for each process measure as well as 30-day
19 and 1-year RSM rates. For acute interventions, the early antithrombotics showed the lowest degree of
20 variance, although the difference between the first and third quartiles remained significant. In
21 contrast, there were twofold to threefold differences in the use of IV rt-PA < 2 hour, DVT
22 prophylaxis, anticoagulant for AF and lipid-lowering medication for LDL \geq 100 mg/dl.

Table 2. Baseline characteristics of patients with acute ischemic stroke in the China National Stroke Registry

	Level	N (%)
Patient characteristics		
Total		12027
Demographics		
Age, yr	Median (IQR)	67 (57-75)
Gender	Male	7407(61.59)
	Female	4620(38.41)
Insurance scheme	UBMIS	7311(60.79)
	NRCMS	2027(16.85)
	Commercial	397(3.30)
	Self-payment	2292(19.06)
Transport to hospital by EMS	Yes	1901(15.81)
NIHSS at admission	Median (IQR)	4 (2-9)
Vascular risk factors		
Previous stroke/TIA	Yes	4088(33.99)
Diabetes	Yes	2593(21.56)
Hypertension	Yes	7672(63.79)
Dyslipidemia	Yes	1344(11.17)
CHD/previous MI	Yes	1748(14.53)
Atrial fibrillation	Yes	892(7.42)
PVD	Yes	76(0.63)
Ever smoking	Yes	4779(39.74)

1			
2			
3			
4	Heavy drinking	Yes	1873(15.57)
5			
6	Pre-existing comorbid conditions		
7			
8	Congestive heart failure	Yes	250(2.08)
9			
10	Valvular heart disease	Yes	288(2.42)
11			
12	Chronic obstructive pulmonary	Yes	138(1.15)
13			
14	Hepatic cirrhosis	Yes	41(0.34)
15			
16	Peptic ulcer disease	Yes	336(2.81)
17			
18	Previous gastrointestinal bleeding	Yes	184(1.54)
19			
20	Dementia/Alzheimer's disease	Yes	156(1.30)
21			
22	Cancer	Yes	215(1.80)
23			
24	Deep venous thrombosis/Pulmonary	Yes	77(0.64)
25			
26	Renal dialysis	Yes	9(0.08)
27			
28	Pre-stroke dependence (mRS>2)	Yes	1120(9.31)
29			
30	Glucose on admission	Yes	2328(19.72)
31			
32			
33			
34	Hospital characteristics		
35			
36	Total		120
37			
38	Hospital size		
39			
40	Beds	Median (IQR)	1200 (700, 1 861)
41			
42	Hospital type		
43			
44	Teaching	Yes	62(51.67)
45			
46	Annual stroke discharges	Median (IQR)	430 (310,601)
47			
48	Geographic region		
49			
50	East	Yes	70 (58.33)
51			
52	Middle	Yes	26 (21.67)
53			
54			
55			
56			
57			
58			
59			
60			

West	Yes	24 (20.0)
------	-----	-----------

- 1 IQR, interquartile range; UBMIS, urban basic medical insurance scheme; NRCMS, new rural
2 cooperative medical scheme; EMS, emergency medical service; NIHSS, National Institutes of Health
3 Stroke Scale; TIA, transient ischemic attack; CHD, coronary artery disease; MI, myocardial
4 infarction; PVD, peripheral vascular disease; mRS, modified Rankin scale.

For peer review only

1 **Table 3. Hospital performance measures and RSM rates**

Measures	Median (IQR, %)
Composite score	65.65 (59.05-72.75)
Acute interventions	
IV rt-PA < 2 hour	0.00 (0.00-25.00)
Early antithrombotics	80.68 (73.21-88.24)
DVT prophylaxis	59.22 (33.33-70.00)
Discharge interventions	
Discharge antithrombotics	77.00 (64.89-85.15)
Anticoagulation for AF	14.29 (0.00-26.97)
LDL 100	41.89 (25.00-61.72)
Antihypertensive medication	61.37 (45.46-75.00)
Antidiabetic medication	67.03 (53.15-79.58)
Smoking cessation	70.87 (50.55-83.33)
RSM rate	
30-day	5.41 (4.91-6.17)
1-year	13.55 (12.77-14.48)

2 IV, intravenous; rt-PA, recombinant tissue-type plasminogen; DVT, deep vein thrombosis; AF,
3 atrial fibrillation; LDL, low-density lipoprotein; RSM, risk-standardised mortality.

1 **Correlations of performance measures**

2 The correlations between two individual hospital performance measures varied widely (Table 4).
3 After bonferroni correction ($P < 0.001$), we found moderate correlations (Spearman correlation
4 coefficients ≥ 0.40 ; $P < 0.001$ for all) for all pairwise comparisons between antithrombotic at
5 discharge and lipid-lowering drugs for $LDL \geq 100$ mg/dl, antihypertensive medication, and
6 antidiabetic medication; and between antidiabetic medication and antihypertensive medication and
7 smoking cessation at discharge. Other hospital performance measures had modest correlations or no
8 correlations with each other (Spearman correlation coefficient < 0.40 for all).

9 **Association of performance measures with hospital-level RSM rates**

10 The median 30-day and 1-year RSM rates (IQR) were 5.41% (4.91%–6.17%) and 13.55%
11 (12.77%–14.48%), respectively (Table 3). The ICC of 30-day RSM rate was 0.065, and the ICC of
12 1-year RSM rate was 0.041.

13 All performance measures showed no correlations with 30-day RSM rate. Several performance
14 measures showed statistically significant, but modest, correlations with 1-year RSM rate, including
15 antithrombotics at discharge (Spearman correlation coefficients = 0.32), antihypertensive medication
16 (Spearman correlation coefficients = 0.30) and antidiabetic medication (Spearman correlation
17 coefficients = 0.31) ($P < 0.05$ for all) (Table 4). These performance measures individually explained
18 between 0.04% and 5.02% of hospital-level variation in 30-day RSM rate, and between 0.08% and
19 10.05% of hospital-level variation in 1-year RSM rate (Table 5).

20 No correlation was observed between the hospital-level composite score and 30-day RSM rate
21 (Spearman correlation coefficients = 0.16). Modest correlation was observed between the
22 hospital-level composite score and 1-year RSM rate (Spearman correlation coefficients = 0.32). The

-
- 1 composite score explained 2.53% and 10.18% of the hospital-level variation in 30-day and 1-year
 - 2 RSM rates, respectively (Table 5).

For peer review only

Table 4. Correlation coefficients for performance measures and hospital RSM rates (30-day and 1-year)

	Acute interventions			Discharge interventions						
	IV rt-PA < 2 hour	Early antithrombotics	DVT prophylaxis	Antithrombotics	Anticoagulation for AF	Lipid-lowering drug for LDL ≥ 100 mg/dl	Antihypertensive medication	Antidiabetic medication	Smoking cessation	Composite score
Acute interventions										
IV rt-PA < 2 hour	1.00									
Early antithrombotics	0.01	1.00								
DVT prophylaxis	0.08	0.23	1.00							
Discharge interventions										
Antithrombotics	0.01	0.34*	0.03	1.00						
Anticoagulation for AF	-0.01	0.04	0.19	0.16	1.00					
LDL 100	0.08	0.13	0.07	0.44*	0.26*	1.00				
Antihypertensive medication	-0.02	0.08	-0.09	0.59*	0.12	0.27*	1.00			
Antidiabetic medication	0.04	0.10	0.07	0.66*	0.17	0.31*	0.64*	1.00		

Smoking cessation	-0.01	0.34*	0.01	0.34*	0.25*	0.13	0.21	0.26*	1.00	
Composite score	0.05	0.48*	0.24	0.79*	0.32*	0.69*	0.60*	0.62*	0.47*	1.00
Risk-standardized 30-day mortality rate	-0.16	-0.02	-0.06	-0.16	0.04	-0.09	-0.17	-0.22	-0.04	-0.16
Risk-standardized 1-year mortality rate	-0.12	-0.03	-0.11	-0.32*	-0.07	-0.22	-0.30*	-0.31*	-0.02	-0.32*

IV, intravenous; rt-PA, recombinant tissue-type plasminogen; DVT, deep vein thrombosis; AF, atrial fibrillation; LDL, low-density

lipoprotein; RSM, risk-standardised mortality.

*P<0.001.

Table 5. Variance in 30-day and 1-year RSM rates explained by each performance measure and the composite measure

Measures	30-day RSM rate	1-year RSM rate
	% variance explained	% variance explained
Acute interventions		
IV rt-PA < 2 hour	2.43%	1.32%
Early antithrombotics	0.04%	0.08%
DVT prophylaxis	0.38%	1.14%
Discharge interventions		
Discharge antithrombotics	2.59%	10.05%
Anticoagulation for AF	0.14%	0.45%
LDL 100	0.76%	4.67%
Antihypertensive medication	2.99%	9.24%
Antidiabetic medication	5.02%	9.49%
Smoking cessation	0.18%	0.06%
Composite score	2.53%	10.18%

IV, intravenous; rt-PA, recombinant tissue-type plasminogen; DVT, deep vein thrombosis; AF, atrial fibrillation; LDL, low-density lipoprotein; RSM, risk-standardised mortality.

1 DISCUSSION

2 The present study found that ischemic stroke care was suboptimal in China and there were various
3 correlations among hospital performance measures. The hospital-level composite score had no
4 correlation with 30-day RSM rate and a modest correlation with 1-year RSM rate. This finding
5 suggested hospital performance measures cannot reliably infer short- and long- term mortalities after
6 acute ischemic stroke. Our results underscored that the current performance measures of stroke care
7 provided complementary, but not redundant, information with the measures of 30-day and 1-year
8 mortalities.

9 When compared our data with the GWTG-Stroke in America, we found that ischemic stroke care
10 was suboptimal in China. The GWTG-Stroke program was developed by the AHA/ASA as a national
11 stroke registry and performance improvement program with the primary goal of improving the
12 quality of care and outcomes of stroke and TIA in America.^{7 14} The comparison showed that many
13 hospital performance measures in China were far down from the GWTG-Stroke,^{14 23} including the
14 composite score (63.3% in 2007 CNSR versus 94.0% in 2007 GWTG-Stroke), IV rt-PA < 2 hour
15 (14.1% in 2007 CNSR versus 72.8% in 2007 GWTG-Stroke), early antithrombotics (80.3% in 2007
16 CNSR versus 97.0% in 2007 GWTG-Stroke), DVT prophylaxis (59.6% in 2007 CNSR versus 89.5%
17 in 2007 GWTG-Stroke), discharge antithrombotics (71.0% in 2012 CNSR versus 98.9% in 2007
18 GWTG-Stroke), anticoagulation for AF (19.7% in 2007 CNSR versus 98.4% in 2007 GWTG-Stroke),
19 lipid-lowering drug for LDL \geq 100 mg/dL (42.6% in 2012 CNSR versus 88.3% in 2007
20 GWTG-Stroke), and smoking cessation (63.3% in 2007 CNSR versus 93.6% in 2007 GWTG-Stroke).
21 Financial burden, lacking of stroke center certification and stroke education might be the main
22 reasons.

1 The relationships between performance measures and stroke outcomes remained uncertainty.
2
3
4
5
6 Some studies have indicated that the use of performance measures was associated with lower
7
8 short-term mortality and better functional outcomes.²⁴⁻²⁶ However, the links between these stroke
9
10 performance measures and outcomes were not clear in other studies.²⁷⁻³⁰ There were several probable
11
12 reasons for the modest correlations between hospital-level performance measures and RSMs in the
13
14 present study. Firstly, although clinical trials have shown significant relationships between
15
16 performance measures and outcomes,^{31 32} the evidence-based performance measures were not mainly
17
18 designed for overall short- and long-term hospital mortalities. Secondly, there was relative little
19
20 variation across hospitals in some performance measures, such as early antithrombotics after
21
22 admission, which limited the ability to discriminate between hospitals based on their performance on
23
24 these measures. Additionally, some performance measures, such as IV, may have a greater effect
25
26 regarding stroke-related disability than mortality.³³ Finally, hospital mortalities, even
27
28 risk-standardised ones, were likely affected by many factors independent of the performance
29
30 measures of stroke care quality, such as severity of stroke, patients' or their family's preference,
31
32 economic level and clinical strategies that may contribute to a hospital's performance outcomes.³⁴

33
34
35
36
37
38
39
40 The present study also demonstrated significant correlations between certain evidence-based
41
42 performance measures for acute ischemic stroke care, indicating that hospitals performing well in
43
44 one performance measure were more likely to perform well in other measures. However, other
45
46 performance measures were less strongly correlated with each other. This finding implies different
47
48 performance measures reflect separate components of quality in acute ischemic stroke care. Our
49
50 work indicated that hospital performance rankings were likely to be substantially affected by the
51
52
53
54
55
56
57
58
59
60

1 performance measures under selection. A broader range of performance measures may be needed to
2 comprehensively reflect the quality of stroke care.

3 Our study had several strengths. First, to date, the CNSR was the largest stroke database in China.
4 Hospitals participating in the CNSR encompassed different regions and had good representativeness.
5 Second, we used the newer RSM method based on hierarchical models to account for variation in
6 case numbers across hospitals or for intra-hospital clustering effects.¹⁵ Third, baseline characteristics
7 of patients, such as age, gender, vascular risk factors, comorbid conditions, and stroke severity
8 (NIHSS) were adjusted in calculating the RSMs in accordance with the American Heart
9 Association/American Stroke Association (AHA/ASA).^{15 34} Additionally, besides short-term RSM,
10 our study also analysed long-term RSM.

11 However, our study also had some limitations. Firstly, our study was observational and
12 non-randomised. The association between stroke care performance and stroke outcomes did not
13 necessarily prove causality and may be confounded by previously discussed factors. Secondly, our
14 outcome was mortality; other outcomes such as stroke recurrence and functional outcomes were also
15 vital to patients, which should be assessed in future studies.³⁰ Thirdly, the hospital performance
16 measures, stroke outcomes, and the relationships between them might vary over time (such as
17 extended time window for thrombolysis). Future research need to determine the stability of the
18 process-outcome relationship as quality improvement efforts would drive broader care adoption.
19 Fourthly, our data were collected between 2007 and 2008, therefore the interpretation of our data
20 might be limited. Future research is needed to confirm our results. Finally, there were several
21 differences in stroke healthcare delivery systems between China and other countries. The results

1 reported herein came from the Chinese healthcare system and therefore may not necessarily be
2 generalisable to other countries.

3 **CONCLUSIONS**

4 The adherence to evidence-based performance measures for acute ischemic stroke was suboptimal
5 in China. There were various correlations among hospital individual performance measures. The
6 hospital performance measures had no correlations with 30-day RSM rate and modest correlations
7 with 1-year RSM rate. More measures are needed to assess and improve the quality of hospital-level
8 stroke care in China.

1 **Acknowledgements**

2 We thank all participating hospitals, colleagues, nurses, imaging and laboratory technicians, and
3 the CNSR Steering Committee members.

4 **Contributorship Statement**

5 XMZ and ZXL analyzed the data and wrote the manuscript. XLB, LPL, CXW, HL, JB, QY and
6 DW analyzed and interpreted the data. ZXL, CJW, YJ, XMY and XMZ performed research. YJW,
7 YLW, ZXL, YX and XQZ conceived, designed and supervised the study.

8 **Funding**

9 Supported by grants from the Ministry of Science and Technology of the People's Republic of
10 China (2006BA101A11, 2008ZX09312-008, 2011BAI08B01, 2011BAI08B02, 2012ZX09303,
11 2013BAI09B14, 2013BAI09B03, 2015BAI12B02, 2015BAI12B04, 2017YFC1310900 and
12 2017YFC1310901), grants from the Beijing Municipal Science and Technology Commission
13 (D15110700200000, D151100002015001, D151100002015002, Z161100000516223 and
14 Z141107002514125), and the Beijing Tiantan Hospital Seeding Initiative.

15 **Competing interests**

16 None.

17 **Ethics approval**

18 Approval was obtained from the Central Institutional Review Board at Beijing Tiantan Hospital.

19 **Provenance and peer review**

20 Not commissioned; externally peer reviewed.

21 **Data sharing statement:** No additional data are available.

1 References

- 1 1. Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990-2013:
2 a systematic subnational analysis for the Global Burden of Disease Study 2013. *Lancet*
3 2016;387:251-72.
- 4 2. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic
5 stroke or transient ischemic attack: a statement for healthcare professionals from the
6 American Heart Association/American Stroke Association Council on Stroke: co-sponsored
7 by the Council on Cardiovascular Radiology and Intervention: the American Academy of
8 Neurology affirms the value of this guideline. *Stroke* 2006;37:577-617.
- 9 3. Adams HP, Jr., del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with
10 ischemic stroke: a guideline from the American Heart Association/American Stroke
11 Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and
12 Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of
13 Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of
14 Neurology affirms the value of this guideline as an educational tool for neurologists.
15 *Circulation* 2007;115:e478-534.
- 16 4. Wang YJ, Zhang SM, Zhang L, et al. Chinese guidelines for the secondary prevention of ischemic
17 stroke and transient ischemic attack 2010. *CNS Neurosci Ther* 2012;18:93-101.
- 18 5. Reeves MJ, Arora S, Broderick JP, et al. Acute stroke care in the US: results from 4 pilot
19 prototypes of the Paul Coverdell National Acute Stroke Registry. *Stroke* 2005;36:1232-40.
- 20 6. Hinchey JA, Shephard T, Tonn ST, et al. Benchmarks and determinants of adherence to stroke
21 performance measures. *Stroke* 2008;39:1619-20.

- 1 7. Fonarow GC, Reeves MJ, Smith EE, et al. Characteristics, performance measures, and in-hospital
2 outcomes of the first one million stroke and transient ischemic attack admissions in get with
3 the guidelines-stroke. *Circ Cardiovasc Qual Outcomes* 2010;3:291-302.
- 4 8. LaBresh KA, Reeves MJ, Frankel MR, et al. Hospital treatment of patients with ischemic stroke or
5 transient ischemic attack using the "Get With The Guidelines" program. *Arch Intern Med*
6 2008;168:411-7.
- 7 9. Ellrodt AG, Fonarow GC, Schwamm LH, et al. Synthesizing lessons learned from get with the
8 guidelines: the value of disease-based registries in improving quality and outcomes.
9 *Circulation* 2013;128:2447-60.
- 10 10. Measuring and improving quality of care: a report from the American Heart
11 Association/American College of Cardiology First Scientific Forum on Assessment of
12 Healthcare Quality in Cardiovascular Disease and Stroke. *Circulation* 2000;101:1483-93.
- 13 11. Alberts MJ, Latchaw RE, Jagoda A, et al. Revised and updated recommendations for the
14 establishment of primary stroke centers: a summary statement from the brain attack coalition.
15 *Stroke* 2011;42:2651-65.
- 16 12. Krumholz HM, Keenan PS, Brush JE, Jr., et al. Standards for measures used for public reporting
17 of efficiency in health care: a scientific statement from the American Heart Association
18 Interdisciplinary Council on Quality of Care and Outcomes Research and the American
19 College of Cardiology Foundation. *Circulation* 2008;118:1885-93.
- 20 13. Lindenauer PK, Remus D, Roman S, et al. Public reporting and pay for performance in hospital
21 quality improvement. *N Engl J Med* 2007;356:486-96.
- 22 14. Schwamm LH, Fonarow GC, Reeves MJ, et al. Get With the Guidelines-Stroke is associated with

- 1
2
3
4 1 sustained improvement in care for patients hospitalized with acute stroke or transient
5
6 2 ischemic attack. *Circulation* 2009;119:107-15.
7
8 3 15. Katzan IL, Spertus J, Bettger JP, et al. Risk adjustment of ischemic stroke outcomes for
9
10 4 comparing hospital performance: a statement for healthcare professionals from the American
11
12 5 Heart Association/American Stroke Association. *Stroke* 2014;45:918-44.
13
14
15 6 16. Wang Y, Cui L, Ji X, et al. The China National Stroke Registry for patients with acute
16
17 7 cerebrovascular events: design, rationale, and baseline patient characteristics. *Int J Stroke*
18
19 8 2011;6:355-61.
20
21
22 9 17. Wang Y, Liao X, Zhao X, et al. Using recombinant tissue plasminogen activator to treat acute
23
24 10 ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry
25
26 11 (CNSR). *Stroke* 2011;42:1658-64.
27
28
29 12 18. Ministry of health of the people's republic of china . Annual report on health statistics of china
30
31 13 2010 [in chinese] . Beijing, china : Publishing house of the peking union medical college ;
32
33 14 2010.
34
35
36 15 19. Peterson ED, DeLong ER, Masoudi FA, et al. ACCF/AHA 2010 Position Statement on Composite
37
38 16 Measures for Healthcare Performance Assessment: a report of the American College of
39
40 17 Cardiology Foundation/American Heart Association Task Force on Performance Measures
41
42 18 (Writing Committee to develop a position statement on composite measures). *Circulation*
43
44 19 2010;121:1780-91.
45
46
47 20 20. Shahian DM, Torchiana DF, Shemin RJ, et al. Massachusetts cardiac surgery report card:
48
49 21 implications of statistical methodology. *Ann Thorac Surg* 2005;80:2106-13.
50
51
52 22 21. Krumholz HM, Wang Y, Mattera JA, et al. An administrative claims model suitable for profiling
53
54
55
56
57
58
59
60

- 1 hospital performance based on 30-day mortality rates among patients with an acute
2 myocardial infarction. *Circulation* 2006;113:1683-92.
- 3 22. Bradley EH, Herrin J, Elbel B, et al. Hospital quality for acute myocardial infarction: correlation
4 among process measures and relationship with short-term mortality. *JAMA* 2006;296:72-8.
- 5 23. Li Z, Wang C, Zhao X, et al. Substantial Progress Yet Significant Opportunity for Improvement
6 in Stroke Care in China. *Stroke* 2016;47:2843-49.
- 7 24. Tung YC, Jeng JS, Chang GM, et al. Processes and outcomes of ischemic stroke care: the
8 influence of hospital level of care. *Int J Qual Health Care* 2015;27:260-6.
- 9 25. Hsieh FI, Lien LM, Chen ST, et al. Get With the Guidelines-Stroke performance indicators:
10 surveillance of stroke care in the Taiwan Stroke Registry: Get With the Guidelines-Stroke in
11 Taiwan. *Circulation* 2010;122:1116-23.
- 12 26. Micieli G, Cavallini A, Quaglini S, et al. Guideline compliance improves stroke outcome: a
13 preliminary study in 4 districts in the Italian region of Lombardia. *Stroke* 2002;33:1341-7.
- 14 27. Adelman EE, Lisabeth LD, Smith MA, et al. Stroke Performance Measures Do Not Predict
15 Functional Outcome. *Neurohospitalist* 2017;7:113-21.
- 16 28. McNaughton H, McPherson K, Taylor W, et al. Relationship between process and outcome in
17 stroke care. *Stroke* 2003;34:713-7.
- 18 29. Parker C, Schwamm LH, Fonarow GC, et al. Stroke quality metrics: systematic reviews of the
19 relationships to patient-centered outcomes and impact of public reporting. *Stroke*
20 2012;43:155-62.
- 21 30. Salinas J, Sprinkhuizen SM, Ackerson T, et al. An International Standard Set of Patient-Centered
22 Outcome Measures After Stroke. *Stroke* 2016;47:180-6.

-
- 1 31. Jauch EC, Saver JL, Adams HP, Jr., et al. Guidelines for the early management of patients with
2 acute ischemic stroke: a guideline for healthcare professionals from the American Heart
3 Association/American Stroke Association. *Stroke* 2013;44:870-947.
- 4 32. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients
5 with stroke and transient ischemic attack: a guideline for healthcare professionals from the
6 American Heart Association/American Stroke Association. *Stroke* 2014;45:2160-236.
- 7 33. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute
8 ischemic stroke. *N Engl J Med* 2008;359:1317-29.
- 9 34. Fonarow GC, Alberts MJ, Broderick JP, et al. Stroke outcomes measures must be appropriately
10 risk adjusted to ensure quality care of patients: a presidential advisory from the American Heart
11 Association/American Stroke Association. *Stroke* 2014;45:1589-601.

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	✓ Page 3 (a) Indicate the study's design with a commonly used term in the title or the abstract
		✓ Page 3 (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2	✓ Page 5 Explain the scientific background and rationale for the investigation being reported
Objectives	3	✓ Page 5 State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	✓ Page 5 Present key elements of study design early in the paper
Setting	5	✓ Page 6 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	✓ Page 5 (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
		(b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	7	✓ Page 7-10 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	✓ Page 7-10 For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	✓ Page 21 Describe any efforts to address potential sources of bias
Study size	10	✓ Page 10 Explain how the study size was arrived at
Quantitative variables	11	✓ Page 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	✓ Page 11 (a) Describe all statistical methods, including those used to control for confounding
		✓ Page 11 (b) Describe any methods used to examine subgroups and interactions
		✓ Page 11 (c) Explain how missing data were addressed
		(d) If applicable, explain how loss to follow-up was addressed
		(e) Describe any sensitivity analyses
Results		
Participants	13*	✓ Page 11 (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
		✓ Page 11 (b) Give reasons for non-participation at each stage
		(c) Consider use of a flow diagram
Descriptive data	14*	✓ Page 11 (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
		✓ Page 11 (b) Indicate number of participants with missing data for each variable of interest
		✓ Page 11 (c) Summarise follow-up time (eg, average and total amount)
Outcome data	15*	✓ Page 16 Report numbers of outcome events or summary measures over time
Main results	16	✓ Page 17-19 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which

		confounders were adjusted for and why they were included
		✓ Page 12-15 (b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	✓ Page 16-19 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	✓ Page 20 Summarise key results with reference to study objectives
Limitations	19	✓ Page 21 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	✓ Page 20-21 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	✓ Page 21-22 Discuss the generalisability (external validity) of the study results
Other information		
Funding	22	✓ Page 23 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

Relationship between Hospital Performance Measures and Outcomes in Patients with Acute Ischemic Stroke: a Prospective Cohort Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020467.R3
Article Type:	Research
Date Submitted by the Author:	17-May-2018
Complete List of Authors:	<p>Zhang, Xinmiao; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Li, Zixiao; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Zhao, Xingquan; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Xian, Ying; Department of Neurology, Duke Clinical Research Institute, Duke University,</p> <p>Liu, Liping; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Wang, Chunxue; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Wang, Chunjuan; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Li, Hao; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Prvu Bettger, J; Department of Neurology, Duke Clinical Research Institute, Duke University; Duke University School of Nursing, Duke University</p> <p>Yang, Qing; Duke University School of Nursing, Duke University</p> <p>Wang, David; INI Stroke Network, OSF Healthcare System, University of Illinois College of Medicine</p> <p>Jiang, Yong; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Bao, Xiaolei; Statistical Analysis Office, Department of Information, General Hospital of Lanzhou Military Area Command</p> <p>Yang, Xiaomeng; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Wang, Yilong; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases</p> <p>Wang, Yongjun; Department of Neurology, Beijing Tiantan Hospital, Capital</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Medical University; China National Clinical Research Center for Neurological Diseases
Primary Subject Heading:	Neurology
Secondary Subject Heading:	Evidence based practice
Keywords:	Hospital performance, Ischemic stroke, Quality and outcomes, Mortality

SCHOLARONE™
Manuscripts

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2017-020467 on 1 August 2018. Downloaded from <http://bmjopen.bmj.com/> on April 20, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Title pages**

2 **Relationship between Hospital Performance Measures and Outcomes in Patients with Acute**
3 **Ischemic Stroke: a Prospective Cohort Study**

4 Xinmiao Zhang^{1,2,3,4,#}, Zixiao Li^{1,2,3,4,#}, Xingquan Zhao^{1,2,3,4}, Ying Xian⁵, Liping Liu^{1,2,3,4},
5 Chunxue Wang^{1,2,3,4}, Chunjuan Wang^{1,2,3,4}, Hao Li^{1,2,3,4}, Janet Bettger^{5,6}, Qing Yang⁶, David
6 Wang⁷, Yong, Jiang^{1,2,3,4}, Xiaolei Bao⁸, Xiaomeng Yang^{1,2,3,4}, Yilong Wang^{1,2,3,4,*}, Yongjun
7 Wang^{1,2,3,4,*}; on behalf of China National Stroke Registries

8 ¹ Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

9 ² China National Clinical Research Center for Neurological Diseases, Beijing, China

10 ³ Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China

11 ⁴ Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China

12 ⁵ Department of Neurology, Duke Clinical Research Institute, Duke University, Durham, NC, USA

13 ⁶ Duke University School of Nursing, Duke University, Durham, NC, USA

14 ⁷ INI Stroke Network, OSF Healthcare System, University of Illinois College of Medicine, Peoria, IL,
15 USA

16 ⁸ Statistical Analysis Office, Department of Information, General Hospital of Lanzhou Military Area
17 Command, Lanzhou, Gansu, China

18
19 # Xinmiao Zhang and Zixiao Li contributed equally to this work.

20
21 * **Corresponding author:**

22 **Yongjun Wang: E-mail address:** yongjunwang1962@gmail.com

23 Yongjun Wang and Yilong Wang contributed equally to this paper.

1
2
3
4 1 **Key words:** Hospital performance; Ischemic stroke; Quality and outcomes; Mortality

5
6 2 **Word count:** 3764
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1 **Relationship between Hospital Performance Measures and Outcomes in Patients with Acute**
2
3
4 **Ischemic Stroke: a Prospective Cohort Study**

5
6
7
8 **ABSTRACT**

9
10 **Objectives:** Evidence-based performance measures have been increasingly used to evaluate the
11 hospital quality of stroke care, but their impact on stroke outcomes has not been verified. We aimed
12 to evaluate the correlations between hospital performance measures and outcomes among acute
13 ischemic stroke patients in Chinese population.

14 **Methods:** Data was derived from a prospective cohort, which included 120 hospitals participating in
15 the China National Stroke Registry between September 2007 and August 2008. Adherence to
16 evidence-based performance measures was examined, and the composite score of hospital
17 performance measures was calculated. Primary stroke outcomes were hospital-level, 30-day and
18 1-year risk-standardized mortality (RSM). Associations of individual performance measures and
19 composite score with stroke outcomes were assessed by using Spearman correlation coefficients.

20 **Results:** One hundred and twenty hospitals that recruited 12,027 patients with ischemic stroke were
21 included in our analysis. Among 12,027 patients, 61.59% were men, and the median age was 67
22 years. The overall composite score of performance measures was 63.3%. The correlation coefficients
23 between individual performance measures ranged widely from 0.01 to 0.66. No association was
24 observed between the composite score and 30-day RSM. The composite score was modestly
25 associated with 1-year RSM (Spearman correlation coefficients, 0.34; $P < 0.05$). The composite score
26 explained only 2.53% and 10.18% of hospital-level variation in 30-day and 1-year RSMs for acute
27 stroke patients.

1
2
3
4 1 **Conclusions:** The adherence to evidence-based performance measures for acute ischemic stroke was
5
6 2 suboptimal in China. There were various correlations among hospital individual performance
7
8 3 measures. The hospital performance measures had no correlations with 30-day RSM rate and modest
9
10
11 4 correlations with 1-year RSM rate.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4 **1 Article summary**

5
6 **2 Strengths and limitations of this study:**

7
8
9 3 1. As the largest stroke database in China, hospitals participating in the China National Stroke

10
11 4 Registry encompassed different regions and had good representativeness.

12
13 5 2. We used the newer risk-standardized mortality method based on hierarchical models to account for

14
15 6 variation in case numbers across hospitals or for intra-hospital clustering effects.

16
17 7 3. Our study was observational and non-randomised. The association between hospital performance

18
19 8 measures and stroke outcomes did not necessarily prove causality.

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 9

1 INTRODUCTION

2 Stroke remains to be the leading cause of mortality in China, which was responsible for around 1.9
3 million deaths in 2013.¹ Although evidence-based guidelines for stroke and transient ischemic
4 attack (TIA) have been developed and updated over time,²⁻⁴ there were variations and deficiencies
5 in how these guidelines were applied.⁵⁻⁷ To reduce the national stroke burden, several national
6 organizations have developed a set of evidence-based hospital performance measures to quantify
7 and promote the quality of stroke care.⁷⁻⁹

8 Evidence-based hospital performance measures evaluated the structure, process and outcome of
9 stroke care, and provided a metric that could be tracked, reported and improved.¹⁰ Evidence-based
10 hospital performance measures have also been increasingly used for certification of stroke centres,¹¹
11 public reporting¹² and remuneration for performance.¹³ Although there has been substantial
12 improvement in stroke care quality in China, gaps still exist in adherence to the evidence-based
13 hospital performance measures. In addition, although measuring outcomes after stroke has important
14 policy implications,¹⁴ there has been limited evidence demonstrating the association between
15 adherence to performance measures and better patient outcomes.¹⁵

16 The China National Stroke Registry (CNSR) was a national hospital-based, prospective stroke
17 registry, which encompassed different regions and had good representativeness.¹⁶ CNSR thoroughly
18 investigated all indicators related to the quality of stroke care, including evidence-based acute
19 performance measures and performance measures at discharge. Thus, it could reflect the real
20 situation of stroke care in China. Using data from the CNSR, we sought to determine whether
21 evidence-based hospital performance measures were associated with short- and long-term outcomes
22 in acute ischemic stroke patients in China. Specifically, we (1) reported the hospital variations in
23 adherence to evidence-based performance measures, (2) assessed the correlations between each

1 individual performance measures, and (3) quantified the associations between the performance
2 measures and hospital-level, risk-standardised, 30-day and 1-year mortalities among acute ischemic
3 stroke patients in China.

4 **METHODS**

5 **CNSR overview**

6 The CNSR was the first nationwide, hospital-based, prospective stroke registry of quality assessment
7 in China, which conducted between September 2007 and August 2008. It was sponsored by the
8 Ministry of Health of the People's Republic of China to establish a national stroke database to
9 evaluate the stroke care quality and outcomes. The study design of CNSR has been described
10 previously.¹⁶ Briefly, the criteria used for hospital selection included: (1) having at least one stroke
11 neurologist, (2) at least two sites were included from each of the 31 provinces and municipalities in
12 mainland China, (3) commitment to participate voluntarily and (4) ability to conduct research.^{16 17}

13 The CNSR recruited consecutive patients older than 18 years and diagnosed with ischemic stroke,
14 TIA, intracerebral haemorrhage, or subarachnoid haemorrhage within 14 days of the index event. We
15 collected patients' demographics, adherence to performance measures during hospitalization, and
16 status at discharge, 90-day, 6-month and 1-year follow-up after symptom onset. The study was
17 approved by the Central Institutional Review Board of Beijing Tiantan Hospital. Written informed
18 consent was acquired from the patient or the legally authorised representative.

19 **Data collection**

20 Hospitals' characteristics were surveyed. According to annual report on health statistics of China,¹⁸
21 hospitals were divided into three regions: eastern, central and western. Academic status was defined
22 as being affiliated with a specific university or not. Hospital bed size was the number of total

1 inpatient beds per site. Annual stroke discharge was the number of discharged patients diagnosed
2 with stroke per year of each participating hospital.

3 Trained research coordinators at each hospital reviewed medical records daily to identify, obtain
4 informed consent, and enrol consecutive patients in accordance with the procedures indicated in a
5 standard data collection manual. The key variables in the CNSR were assessed, including: (1)
6 demographic characteristics and medical history; (2) pre-stroke modified Rankin scale (mRS) and
7 National Institutes of Health Stroke Scale (NIHSS) at admission, vascular risk factors, and clinical
8 care during hospitalization; and (3) 30-day and 1-year all-cause mortalities after stroke. Patients or
9 their authorised caregivers were contacted via telephone by trained research personnel with
10 standardised scripts for follow-up at 90 days, 6 months and 1 year after stroke symptom onset.¹⁶
11 Specific death events and dates were recorded in detail, and 30-day and 1-year all-cause mortalities
12 after stroke were confirmed.

13 **Performance Measures**

14 We evaluated nine hospital performance measures, including seven “core” measures for acute
15 ischemic stroke as recommended by the American Heart Association/American Stroke Association
16 (AHA/ASA) Get With The Guidelines-Stroke (GWTG-Stroke)⁷ and two additional evidence-based
17 secondary prevention metrics.⁴ These seven core performance measures included (1) intravenous
18 tissue-type plasminogen activator (tPA) in patients who arrived within 2 hours after symptom onset
19 and treated within 3 hours (IV rt-PA < 2 hour), (2) antithrombotic medication within 48 hours of
20 admission (early antithrombotics), (3) deep vein thrombosis (DVT) prophylaxis within 48 hours of
21 admission for nonambulatory patients (DVT prophylaxis), (4) antithrombotic medication, (5)
22 anticoagulation for atrial fibrillation (AF) , (6) medications for lowering low-density lipoprotein

1 (LDL) ≥ 100 mg/dL, (7) smoking cessation. The two additional performance measures were
2 antihypertensive medication for patients with hypertension and hypoglycemia medication for
3 diabetes mellitus. Details of the performance measures were described in Table 1.

4 Adherence to hospital-level individual performance measures was calculated as the proportion of
5 patients who received the indicated care among all the patients who were eligible for the indicated
6 care. The overall hospital performance measures were measured as the composite score, which was
7 calculated by the total number of interventions actually performed among all eligible patients at a
8 hospital, divided by the total number of recommended interventions in all eligible patients.¹⁹
9 Although the composite score was analysed as a continuous variable, hospitals were also divided, for
10 descriptive purposes, into quartiles based on this continuous variable. To ensure the stability of the
11 measure, hospitals with fewer than 20 patients in the denominator of any measures were excluded.

1
2
3
4 **Table 1. Specifications of evidence-based performance measures**

Performance measures of ischemic stroke care	Definition of performance measures for eligible patients*
Acute performance measures	
IV rt-PA < 2 hour	Intravenous recombinant tissue plasminogen activator (IV rtPA) in patients who arrived within 2 hours after initial symptom onset and treated within 3 hours
Early antithrombotics	Antithrombotic therapy prescribed within 48 hours of hospitalization, including antiplatelet or anticoagulant therapy
DVT prophylaxis	Patients at risk for deep vein thrombosis (DVT) (non-ambulatory) who received DVT prophylaxis by end of hospital day two, including pneumatic compression, warfarin sodium or heparin sodium
Performance measures at discharge	
Discharge antithrombotics	Antithrombotic therapy prescribed at discharge
Anticoagulation for atrial fibrillation	Anticoagulation prescribed at discharge for patients with atrial fibrillation or atrial flutter documented during hospitalization
LDL 100	Lipid lowering agent prescribed at discharge if low-density lipoprotein (LDL) ≥ 100 mg/dL
Antihypertensive therapy for hypertension	Antihypertension medication prescribed at discharge for patients with a history of hypertension or hypertension documented during hospitalization

Hypoglycemic therapy for diabetes mellitus	Hypoglycemic medication prescribed at discharge for patients with a history of diabetes mellitus or diabetes mellitus documented during hospitalization
Smoking cessation	Smoking cessation intervention (counseling or medication) prior to discharge for current or recent smokers

1 * Eligible patients were those without any medical contraindications (e.g., treatment intolerance,
 2 excessive risk of adverse reaction, patient/family refusal, or terminal illness/comfort care only) and
 3 documented as reasons for nontreatment for each of the applicable measures. We also excluded
 4 patients who were discharged to hospice, or another short-term general hospital, or against medical
 5 advice before the end of hospital day two. For acute performance measures except for rt-PA measure,
 6 we excluded patients who died before the end of hospital day two. For the acute rt-PA measure, we
 7 excluded patients with missing or erroneous onset, arrival or treatment times, those who began IV
 8 t-PA at an outside hospital, or who initiated IV t-PA after 180 minutes from onset. For performance
 9 measures at discharge, we excluded patients who died during hospitalization. As for seven
 10 performance measures from the Get With The Guideline-Stroke (GWTG-Stroke), we employed the
 11 same criteria as the Get With The Guideline-Stroke (GWTG-Stroke).

1 Risk-standardized Mortality (RSM) Rates

2 RSM rates were calculated using a multivariate hierarchical regression model in accordance with
3 the AHA/ASA recommendations for risk adjustment of ischemic stroke outcomes to compare
4 hospital performance.¹⁵ The first level of the hierarchical model included patient characteristics.
5 These patient's variables were divided into three categories: (1) demographics and clinical features:
6 age, gender, health insurance type (urban basic medical insurance schemes for urban and
7 governmental employees and urban residents, new rural cooperative medical schemes for rural
8 residents, commercial insurance, and self-payment), transport to hospital by emergency medical
9 service, and NIHSS score at admission; (2) vascular risk factors: hypertension, diabetes mellitus,
10 dyslipidaemia, AF, coronary artery disease, previous myocardial infarction, congestive heart failure,
11 valvular heart disease, history of stroke/TIA, peripheral vascular disease, current smoking, and
12 excessive alcohol consumption; (3) other pre-existing comorbid conditions: chronic obstructive
13 pulmonary disease, hepatic cirrhosis, peptic ulcer, previous gastrointestinal bleeding, Alzheimer's
14 disease/dementia, cancer, DVT/pulmonary embolus, renal dialysis, pre-stroke dependence (mRS ≥ 3),
15 and blood glucose at admission. The second level included hospital-specific random intercepts that
16 allow for different baseline mortalities between hospitals. The hospital RSM rates were obtained as
17 the ratio of "predicted" to expected mortality, multiplied by the unadjusted mortalities for the total
18 population.^{20 21} The expected outcome for each hospital was the number of deaths expected at the
19 hospital if the hospital's patients were treated at a "reference" hospital. The predicted hospital-level
20 outcome was the number of expected mortalities at the "specific" hospital and not at a reference
21 hospital.

22 Statistical analyses

1
2
3
4 1 Numbers (percentages) were used to describe categorical variables, and median values with
5
6 2 interquartile ranges (IQRs) were reported for continuous variables. The correlations of individual
7
8 3 performance measures, as well as performance measures and stroke outcomes, were evaluated using
9
10 4 Spearman correlation coefficients. The bonferroni correction was performed in the multiple
11
12 5 comparisons. The inter-class correlation (ICC) of 30-day and 1-year RSM rates were calculated. The
13
14 6 relevant correlation coefficients and the percentage of the hospital-specific variations in RSM rates
15
16 7 were explained using the squares of the correlation coefficients as indicators of the strength of the
17
18 8 associations.²²

19
20
21
22
23 9 All tests were two-tailed, and statistical significance was determined at the α level of 0.05 in
24
25 10 univariate and multivariate analyses. Statistical analysis was performed using SAS 9.3 (SAS Institute
26
27 11 Inc., Cary, NC, USA).

28 29 30 12 **Patient and Public Involvement**

31
32
33 13 No patients were involved in the planning of this study. Patients were recruited via the doctors
34
35 14 and investigators at local hospitals in China. Once the study results have been published in a
36
37 15 peer-reviewed journal, a summary of the main study findings will be distributed in Chinese language
38
39 16 via the local doctors and investigators to the patients.

40 41 42 17 **RESULTS**

43 44 45 18 **Study hospitals and patient baseline characteristics**

46
47 19 Among 14,526 eligible patients diagnosed with acute ischemic stroke from 132 hospitals
48
49 20 throughout China, complete 1-year follow-up information was available for 12,173 patients (83.8%).
50
51 21 We excluded 12 hospitals with fewer than 20 patients in the denominator of any measures. Finally,
52
53 22 120 hospitals that recruited 12,027 patients with ischemic stroke were included in our analysis.
54
55
56
57
58
59
60

1 Hospital and patient baseline characteristics were described in Table 2. Among 120 hospitals, 62
2 (51.67%) hospitals were teaching hospitals and 70 (58.33%) were from eastern regions. The median
3 hospital bed size was 1200 (IQR, 700–1861) and annual stroke volume was 430 (IQR, 310–601).
4 Among 12,027 patients, 7,407 (61.59%) were men, and the median age was 67 (IQR, 57–75) years.
5 Common vascular risk factors included hypertension, previous stroke/ TIA, smoking history, and
6 diabetes. The median NIHSS score was 4 (IQR, 2–9).

7 **Variability in performance measures**

8 The overall composite score was 63.3% among the 120 hospitals. However, the composite score
9 for each hospital varied considerably among the CNSR (Table 3). The hospitals in the highest
10 quartile (quartile 4) had a median (IQR) composite score of 85.1% (82.2%–89.9%), compared with
11 50.9% (44.2%–58.1%) for those in the lowest quartile (quartile 1).

12 In table 3, we showed hospital rates (median and IQR) for each process measure as well as 30-day
13 and 1-year RSM rates. For acute interventions, the early antithrombotics showed the lowest degree of
14 variance, although the difference between the first and third quartiles remained significant. In
15 contrast, there were twofold to threefold differences in the use of IV rt-PA < 2 hour, DVT
16 prophylaxis, anticoagulant for AF and lipid-lowering medication for LDL \geq 100 mg/dl.

Table 2. Baseline characteristics of patients with acute ischemic stroke in the China National Stroke Registry

	Level	N (%)
Patient characteristics		
Total		12027
Demographics		
Age, yr	Median (IQR)	67 (57-75)
Gender	Male	7407(61.59)
	Female	4620(38.41)
Insurance scheme	UBMIS	7311(60.79)
	NRCMS	2027(16.85)
	Commercial	397(3.30)
	Self-payment	2292(19.06)
Transport to hospital by EMS	Yes	1901(15.81)
NIHSS at admission	Median (IQR)	4 (2-9)
Vascular risk factors		
Previous stroke/TIA	Yes	4088(33.99)
Diabetes	Yes	2593(21.56)
Hypertension	Yes	7672(63.79)
Dyslipidemia	Yes	1344(11.17)
CHD/previous MI	Yes	1748(14.53)
Atrial fibrillation	Yes	892(7.42)
PVD	Yes	76(0.63)
Ever smoking	Yes	4779(39.74)

1			
2			
3			
4	Heavy drinking	Yes	1873(15.57)
5			
6	Pre-existing comorbid conditions		
7			
8	Congestive heart failure	Yes	250(2.08)
9			
10	Valvular heart disease	Yes	288(2.42)
11			
12	Chronic obstructive pulmonary	Yes	138(1.15)
13			
14	Hepatic cirrhosis	Yes	41(0.34)
15			
16	Peptic ulcer disease	Yes	336(2.81)
17			
18	Previous gastrointestinal bleeding	Yes	184(1.54)
19			
20	Dementia/Alzheimer's disease	Yes	156(1.30)
21			
22	Cancer	Yes	215(1.80)
23			
24	Deep venous thrombosis/Pulmonary	Yes	77(0.64)
25			
26	Renal dialysis	Yes	9(0.08)
27			
28	Pre-stroke dependence (mRS>2)	Yes	1120(9.31)
29			
30	Glucose on admission	Yes	2328(19.72)
31			
32			
33			
34	Hospital characteristics		
35			
36	Total		120
37			
38	Hospital size		
39			
40	Beds	Median (IQR)	1200 (700, 1 861)
41			
42	Hospital type		
43			
44	Teaching	Yes	62(51.67)
45			
46	Annual stroke discharges	Median (IQR)	430 (310,601)
47			
48	Geographic region		
49			
50	East	Yes	70 (58.33)
51			
52	Middle	Yes	26 (21.67)
53			
54			
55			
56			
57			
58			
59			
60			

West	Yes	24 (20.0)
------	-----	-----------

- 1 IQR, interquartile range; UBMIS, urban basic medical insurance scheme; NRCMS, new rural
2 cooperative medical scheme; EMS, emergency medical service; NIHSS, National Institutes of Health
3 Stroke Scale; TIA, transient ischemic attack; CHD, coronary artery disease; MI, myocardial
4 infarction; PVD, peripheral vascular disease; mRS, modified Rankin scale.

For peer review only

1 **Table 3. Hospital performance measures and RSM rates**

Measures	Median (IQR, %)
Composite score	65.65 (59.05-72.75)
Acute interventions	
IV rt-PA < 2 hour	0.00 (0.00-25.00)
Early antithrombotics	80.68 (73.21-88.24)
DVT prophylaxis	59.22 (33.33-70.00)
Discharge interventions	
Discharge antithrombotics	77.00 (64.89-85.15)
Anticoagulation for AF	14.29 (0.00-26.97)
LDL 100	41.89 (25.00-61.72)
Antihypertensive medication	61.37 (45.46-75.00)
Antidiabetic medication	67.03 (53.15-79.58)
Smoking cessation	70.87 (50.55-83.33)
RSM rate	
30-day	5.41 (4.91-6.17)
1-year	13.55 (12.77-14.48)

2 IV, intravenous; rt-PA, recombinant tissue-type plasminogen; DVT, deep vein thrombosis; AF,
3 atrial fibrillation; LDL, low-density lipoprotein; RSM, risk-standardised mortality.

1 **Correlations of performance measures**

2 The correlations between two individual hospital performance measures varied widely (Table 4).
3 After bonferroni correction ($P < 0.001$), we found moderate correlations (Spearman correlation
4 coefficients ≥ 0.40 ; $P < 0.001$ for all) for all pairwise comparisons between antithrombotic at
5 discharge and lipid-lowering drugs for LDL ≥ 100 mg/dl, antihypertensive medication, and
6 antidiabetic medication; and between antidiabetic medication and antihypertensive medication and
7 smoking cessation at discharge. Other hospital performance measures had modest correlations or no
8 correlations with each other (Spearman correlation coefficient < 0.40 for all).

9 **Association of performance measures with hospital-level RSM rates**

10 The median 30-day and 1-year RSM rates (IQR) were 5.41% (4.91%–6.17%) and 13.55%
11 (12.77%–14.48%), respectively (Table 3). The ICC of 30-day RSM rate was 0.065, and the ICC of
12 1-year RSM rate was 0.041.

13 All performance measures showed no correlations with 30-day RSM rate. Several performance
14 measures showed statistically significant, but modest, correlations with 1-year RSM rate, including
15 antithrombotics at discharge (Spearman correlation coefficients = 0.32), antihypertensive medication
16 (Spearman correlation coefficients = 0.30) and antidiabetic medication (Spearman correlation
17 coefficients = 0.31) ($P < 0.05$ for all) (Table 4). These performance measures individually explained
18 between 0.04% and 5.02% of hospital-level variation in 30-day RSM rate, and between 0.08% and
19 10.05% of hospital-level variation in 1-year RSM rate (Table 5).

20 No correlation was observed between the hospital-level composite score and 30-day RSM rate
21 (Spearman correlation coefficients = 0.16). Modest correlation was observed between the
22 hospital-level composite score and 1-year RSM rate (Spearman correlation coefficients = 0.32). The

-
- 1 composite score explained 2.53% and 10.18% of the hospital-level variation in 30-day and 1-year
 - 2 RSM rates, respectively (Table 5).

For peer review only

Table 4. Correlation coefficients for performance measures and hospital RSM rates (30-day and 1-year)

	Acute interventions			Discharge interventions						
	IV rt-PA < 2 hour	Early antithrombotics	DVT prophylaxis	Antithrombotics	Anticoagulation for AF	Lipid-lowering drug for LDL ≥ 100 mg/dl	Antihypertensive medication	Antidiabetic medication	Smoking cessation	Composite score
Acute interventions										
IV rt-PA < 2 hour	1.00									
Early antithrombotics	0.01	1.00								
DVT prophylaxis	0.08	0.23	1.00							
Discharge interventions										
Antithrombotics	0.01	0.34*	0.03	1.00						
Anticoagulation for AF	-0.01	0.04	0.19	0.16	1.00					
LDL 100	0.08	0.13	0.07	0.44*	0.26*	1.00				
Antihypertensive medication	-0.02	0.08	-0.09	0.59*	0.12	0.27*	1.00			
Antidiabetic medication	0.04	0.10	0.07	0.66*	0.17	0.31*	0.64*	1.00		

Smoking cessation	-0.01	0.34*	0.01	0.34*	0.25*	0.13	0.21	0.26*	1.00	
Composite score	0.05	0.48*	0.24	0.79*	0.32*	0.69*	0.60*	0.62*	0.47*	1.00
Risk-standardized 30-day mortality rate	-0.16	-0.02	-0.06	-0.16	0.04	-0.09	-0.17	-0.22	-0.04	-0.16
Risk-standardized 1-year mortality rate	-0.12	-0.03	-0.11	-0.32*	-0.07	-0.22	-0.30*	-0.31*	-0.02	-0.32*

IV, intravenous; rt-PA, recombinant tissue-type plasminogen; DVT, deep vein thrombosis; AF, atrial fibrillation; LDL, low-density

lipoprotein; RSM, risk-standardised mortality.

*P<0.001.

Table 5. Variance in 30-day and 1-year RSM rates explained by each performance measure and the composite measure

Measures	30-day RSM rate	1-year RSM rate
	% variance explained	% variance explained
Acute interventions		
IV rt-PA < 2 hour	2.43%	1.32%
Early antithrombotics	0.04%	0.08%
DVT prophylaxis	0.38%	1.14%
Discharge interventions		
Discharge antithrombotics	2.59%	10.05%
Anticoagulation for AF	0.14%	0.45%
LDL 100	0.76%	4.67%
Antihypertensive medication	2.99%	9.24%
Antidiabetic medication	5.02%	9.49%
Smoking cessation	0.18%	0.06%
Composite score	2.53%	10.18%

IV, intravenous; rt-PA, recombinant tissue-type plasminogen; DVT, deep vein thrombosis; AF, atrial fibrillation; LDL, low-density lipoprotein; RSM, risk-standardised mortality.

1 DISCUSSION

2 The present study found that ischemic stroke care was suboptimal in China and there were various
3 correlations among hospital performance measures. The hospital-level composite score had no
4 correlation with 30-day RSM rate and a modest correlation with 1-year RSM rate. This finding
5 suggested hospital performance measures cannot reliably infer short- and long- term mortalities after
6 acute ischemic stroke. Our results underscored that the current performance measures of stroke care
7 provided complementary, but not redundant, information with the measures of 30-day and 1-year
8 mortalities.

9 When comparing our data with the GWTG-Stroke in America, we found that ischemic stroke care
10 was suboptimal in China. The GWTG-Stroke program was developed by the AHA/ASA as a national
11 stroke registry and performance improvement program with the primary goal of improving the
12 quality of care and outcomes of stroke and TIA in America.^{7 14} The comparison showed that many
13 hospital performance measures in China were far down from the GWTG-Stroke,^{14 23} including the
14 composite score (63.3% in 2007 CNSR versus 94.0% in 2007 GWTG-Stroke), IV rt-PA < 2 hour
15 (14.1% in 2007 CNSR versus 72.8% in 2007 GWTG-Stroke), early antithrombotics (80.3% in 2007
16 CNSR versus 97.0% in 2007 GWTG-Stroke), DVT prophylaxis (59.6% in 2007 CNSR versus 89.5%
17 in 2007 GWTG-Stroke), discharge antithrombotics (71.0% in 2012 CNSR versus 98.9% in 2007
18 GWTG-Stroke), anticoagulation for AF (19.7% in 2007 CNSR versus 98.4% in 2007 GWTG-Stroke),
19 lipid-lowering drug for LDL ≥ 100 mg/dL (42.6% in 2012 CNSR versus 88.3% in 2007
20 GWTG-Stroke), and smoking cessation (63.3% in 2007 CNSR versus 93.6% in 2007 GWTG-Stroke).
21 Financial burden, lacking of stroke center certification and stroke education might be the main
22 reasons.

1 The relationships between performance measures and stroke outcomes remained uncertainty.
2
3
4
5
6 Some studies have indicated that the use of performance measures was associated with lower
7
8 short-term mortality and better functional outcomes.²⁴⁻²⁶ However, the links between these stroke
9
10 performance measures and outcomes were not clear in other studies.²⁷⁻³⁰ There were several probable
11
12 reasons for the modest correlations between hospital-level performance measures and RSMs in the
13
14 present study. Firstly, although clinical trials have shown significant relationships between
15
16 performance measures and outcomes,^{31 32} the evidence-based performance measures were not mainly
17
18 designed for overall short- and long-term hospital mortalities. Secondly, there was relative little
19
20 variation across hospitals in some performance measures, such as early antithrombotics after
21
22 admission, which limited the ability to discriminate between hospitals based on their performance on
23
24 these measures. Additionally, some performance measures, such as IV, might have a greater effect
25
26 regarding stroke-related disability than mortality.³³ Finally, hospital mortalities, even
27
28 risk-standardised ones, were more likely affected by many factors independent of the performance
29
30 measures of stroke care quality, such as severity of stroke, patients' or their family's preference,
31
32 economic level and clinical strategies that might contribute to a hospital's performance outcomes.³⁴
33
34
35
36
37
38
39

40 The present study also demonstrated significant correlations between certain evidence-based
41
42 performance measures for acute ischemic stroke care, indicating that hospitals performing well in
43
44 one performance measure were more likely to perform well in other measures. However, other
45
46 performance measures were less strongly correlated with each other. This finding implied different
47
48 performance measures reflected separate components of quality in acute ischemic stroke care. Our
49
50 work indicated that hospital performance rankings were likely to be substantially affected by the
51
52
53
54
55
56
57
58
59
60

1 performance measures under selection. A broader range of performance measures may be needed to
2 comprehensively reflect the quality of stroke care.

3 Our study had several strengths. First, to date, the CNSR was the largest stroke database in China.
4 Hospitals participating in the CNSR encompassed different regions and had good representativeness.
5 Second, we used the newer RSM method based on hierarchical models to account for variation in
6 case numbers across hospitals or for intra-hospital clustering effects.¹⁵ Third, baseline characteristics
7 of patients, such as age, gender, vascular risk factors, comorbid conditions, and stroke severity
8 (NIHSS) were adjusted in calculating the RSMs in accordance with the American Heart
9 Association/American Stroke Association (AHA/ASA).^{15 34} Additionally, besides short-term RSM,
10 our study also analysed long-term RSM.

11 However, our study also had some limitations. Firstly, our study was observational and
12 non-randomised. The association between stroke care performance and stroke outcomes did not
13 necessarily prove causality and may be confounded by previously discussed factors. Secondly, our
14 outcome was mortality; other outcomes such as stroke recurrence and functional outcomes were also
15 vital to patients, which should be assessed in future studies.³⁰ Thirdly, the hospital performance
16 measures, stroke outcomes, and the relationships between them might vary over time (such as
17 extended time window for thrombolysis). Future research need to determine the stability of the
18 process-outcome relationship as quality improvement efforts would drive broader care adoption.
19 Fourthly, our data were collected between 2007 and 2008, therefore the interpretation of our data
20 might be limited. Future research is needed to confirm our results. Finally, there were several
21 differences in stroke healthcare delivery systems between China and other countries. The results

1 reported herein came from the Chinese healthcare system and therefore may not necessarily be
2 generalisable to other countries.

3 **CONCLUSIONS**

4 The adherence to evidence-based performance measures for acute ischemic stroke was suboptimal
5 in China. There were various correlations among hospital individual performance measures. The
6 hospital performance measures had no correlations with 30-day RSM rate and modest correlations
7 with 1-year RSM rate. More measures are needed to assess and improve the quality of hospital-level
8 stroke care in China.

1 **Acknowledgements**

2 We thank all participating hospitals, colleagues, nurses, imaging and laboratory technicians, and
3 the CNSR Steering Committee members.

4 **Contributorship Statement**

5 XMZ and ZXL analyzed the data and wrote the manuscript. XLB, LPL, CXW, HL, JB, QY and
6 DW analyzed and interpreted the data. ZXL, CJW, YJ, XMY and XMZ performed research. YJW,
7 YLW, ZXL, YX and XQZ conceived, designed and supervised the study.

8 **Funding**

9 Supported by grants from the Ministry of Science and Technology of the People's Republic of
10 China (2006BA101A11, 2008ZX09312-008, 2011BAI08B01, 2011BAI08B02, 2012ZX09303,
11 2013BAI09B14, 2013BAI09B03, 2015BAI12B02, 2015BAI12B04, 2017YFC1310900 and
12 2017YFC1310901), grants from the Beijing Municipal Science and Technology Commission
13 (D15110700200000, D151100002015001, D151100002015002, Z161100000516223 and
14 Z141107002514125), and the Beijing Tiantan Hospital Seeding Initiative.

15 **Competing interests**

16 None.

17 **Ethics approval**

18 Approval was obtained from the Central Institutional Review Board at Beijing Tiantan Hospital.

19 **Provenance and peer review**

20 Not commissioned; externally peer reviewed.

21 **Data sharing statement:** No additional data are available.

1 References

- 1 1. Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990-2013:
2 a systematic subnational analysis for the Global Burden of Disease Study 2013. *Lancet*
3 2016;387:251-72.
- 4 2. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic
5 stroke or transient ischemic attack: a statement for healthcare professionals from the
6 American Heart Association/American Stroke Association Council on Stroke: co-sponsored
7 by the Council on Cardiovascular Radiology and Intervention: the American Academy of
8 Neurology affirms the value of this guideline. *Stroke* 2006;37:577-617.
- 9 3. Adams HP, Jr., del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with
10 ischemic stroke: a guideline from the American Heart Association/American Stroke
11 Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and
12 Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of
13 Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of
14 Neurology affirms the value of this guideline as an educational tool for neurologists.
15 *Circulation* 2007;115:e478-534.
- 16 4. Wang YJ, Zhang SM, Zhang L, et al. Chinese guidelines for the secondary prevention of ischemic
17 stroke and transient ischemic attack 2010. *CNS Neurosci Ther* 2012;18:93-101.
- 18 5. Reeves MJ, Arora S, Broderick JP, et al. Acute stroke care in the US: results from 4 pilot
19 prototypes of the Paul Coverdell National Acute Stroke Registry. *Stroke* 2005;36:1232-40.
- 20 6. Hinchey JA, Shephard T, Tonn ST, et al. Benchmarks and determinants of adherence to stroke
21 performance measures. *Stroke* 2008;39:1619-20.

- 1 7. Fonarow GC, Reeves MJ, Smith EE, et al. Characteristics, performance measures, and in-hospital
2 outcomes of the first one million stroke and transient ischemic attack admissions in get with
3 the guidelines-stroke. *Circ Cardiovasc Qual Outcomes* 2010;3:291-302.
- 4 8. LaBresh KA, Reeves MJ, Frankel MR, et al. Hospital treatment of patients with ischemic stroke or
5 transient ischemic attack using the "Get With The Guidelines" program. *Arch Intern Med*
6 2008;168:411-7.
- 7 9. Ellrodt AG, Fonarow GC, Schwamm LH, et al. Synthesizing lessons learned from get with the
8 guidelines: the value of disease-based registries in improving quality and outcomes.
9 *Circulation* 2013;128:2447-60.
- 10 10. Measuring and improving quality of care: a report from the American Heart
11 Association/American College of Cardiology First Scientific Forum on Assessment of
12 Healthcare Quality in Cardiovascular Disease and Stroke. *Circulation* 2000;101:1483-93.
- 13 11. Alberts MJ, Latchaw RE, Jagoda A, et al. Revised and updated recommendations for the
14 establishment of primary stroke centers: a summary statement from the brain attack coalition.
15 *Stroke* 2011;42:2651-65.
- 16 12. Krumholz HM, Keenan PS, Brush JE, Jr., et al. Standards for measures used for public reporting
17 of efficiency in health care: a scientific statement from the American Heart Association
18 Interdisciplinary Council on Quality of Care and Outcomes Research and the American
19 College of Cardiology Foundation. *Circulation* 2008;118:1885-93.
- 20 13. Lindenauer PK, Remus D, Roman S, et al. Public reporting and pay for performance in hospital
21 quality improvement. *N Engl J Med* 2007;356:486-96.
- 22 14. Schwamm LH, Fonarow GC, Reeves MJ, et al. Get With the Guidelines-Stroke is associated with

- 1 sustained improvement in care for patients hospitalized with acute stroke or transient
2 ischemic attack. *Circulation* 2009;119:107-15.
- 3 15. Katzan IL, Spertus J, Bettger JP, et al. Risk adjustment of ischemic stroke outcomes for
4 comparing hospital performance: a statement for healthcare professionals from the American
5 Heart Association/American Stroke Association. *Stroke* 2014;45:918-44.
- 6 16. Wang Y, Cui L, Ji X, et al. The China National Stroke Registry for patients with acute
7 cerebrovascular events: design, rationale, and baseline patient characteristics. *Int J Stroke*
8 2011;6:355-61.
- 9 17. Wang Y, Liao X, Zhao X, et al. Using recombinant tissue plasminogen activator to treat acute
10 ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry
11 (CNSR). *Stroke* 2011;42:1658-64.
- 12 18. Ministry of health of the people's republic of china . Annual report on health statistics of china
13 2010 [in chinese] . Beijing, china : Publishing house of the peking union medical college ;
14 2010.
- 15 19. Peterson ED, DeLong ER, Masoudi FA, et al. ACCF/AHA 2010 Position Statement on Composite
16 Measures for Healthcare Performance Assessment: a report of the American College of
17 Cardiology Foundation/American Heart Association Task Force on Performance Measures
18 (Writing Committee to develop a position statement on composite measures). *Circulation*
19 2010;121:1780-91.
- 20 20. Shahian DM, Torchiana DF, Shemin RJ, et al. Massachusetts cardiac surgery report card:
21 implications of statistical methodology. *Ann Thorac Surg* 2005;80:2106-13.
- 22 21. Krumholz HM, Wang Y, Mattera JA, et al. An administrative claims model suitable for profiling

- 1 hospital performance based on 30-day mortality rates among patients with an acute
2 myocardial infarction. *Circulation* 2006;113:1683-92.
- 3 22. Bradley EH, Herrin J, Elbel B, et al. Hospital quality for acute myocardial infarction: correlation
4 among process measures and relationship with short-term mortality. *JAMA* 2006;296:72-8.
- 5 23. Li Z, Wang C, Zhao X, et al. Substantial Progress Yet Significant Opportunity for Improvement
6 in Stroke Care in China. *Stroke* 2016;47:2843-49.
- 7 24. Tung YC, Jeng JS, Chang GM, et al. Processes and outcomes of ischemic stroke care: the
8 influence of hospital level of care. *Int J Qual Health Care* 2015;27:260-6.
- 9 25. Hsieh FI, Lien LM, Chen ST, et al. Get With the Guidelines-Stroke performance indicators:
10 surveillance of stroke care in the Taiwan Stroke Registry: Get With the Guidelines-Stroke in
11 Taiwan. *Circulation* 2010;122:1116-23.
- 12 26. Micieli G, Cavallini A, Quaglini S, et al. Guideline compliance improves stroke outcome: a
13 preliminary study in 4 districts in the Italian region of Lombardia. *Stroke* 2002;33:1341-7.
- 14 27. Adelman EE, Lisabeth LD, Smith MA, et al. Stroke Performance Measures Do Not Predict
15 Functional Outcome. *Neurohospitalist* 2017;7:113-21.
- 16 28. McNaughton H, McPherson K, Taylor W, et al. Relationship between process and outcome in
17 stroke care. *Stroke* 2003;34:713-7.
- 18 29. Parker C, Schwamm LH, Fonarow GC, et al. Stroke quality metrics: systematic reviews of the
19 relationships to patient-centered outcomes and impact of public reporting. *Stroke*
20 2012;43:155-62.
- 21 30. Salinas J, Sprinkhuizen SM, Ackerson T, et al. An International Standard Set of Patient-Centered
22 Outcome Measures After Stroke. *Stroke* 2016;47:180-6.

-
- 1 31. Jauch EC, Saver JL, Adams HP, Jr., et al. Guidelines for the early management of patients with
2 acute ischemic stroke: a guideline for healthcare professionals from the American Heart
3 Association/American Stroke Association. *Stroke* 2013;44:870-947.
- 4 32. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients
5 with stroke and transient ischemic attack: a guideline for healthcare professionals from the
6 American Heart Association/American Stroke Association. *Stroke* 2014;45:2160-236.
- 7 33. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute
8 ischemic stroke. *N Engl J Med* 2008;359:1317-29.
- 9 34. Fonarow GC, Alberts MJ, Broderick JP, et al. Stroke outcomes measures must be appropriately
10 risk adjusted to ensure quality care of patients: a presidential advisory from the American Heart
11 Association/American Stroke Association. *Stroke* 2014;45:1589-601.

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	<p>✓ Page 3 (a) Indicate the study's design with a commonly used term in the title or the abstract</p> <p>✓ Page 3 (b) Provide in the abstract an informative and balanced summary of what was done and what was found</p>
Introduction		
Background/rationale	2	✓ Page 5 Explain the scientific background and rationale for the investigation being reported
Objectives	3	✓ Page 5 State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	✓ Page 5 Present key elements of study design early in the paper
Setting	5	✓ Page 6 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	<p>✓ Page 5 (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up</p> <p>(b) For matched studies, give matching criteria and number of exposed and unexposed</p>
Variables	7	✓ Page 7-10 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	✓ Page 7-10 For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	✓ Page 21 Describe any efforts to address potential sources of bias
Study size	10	✓ Page 10 Explain how the study size was arrived at
Quantitative variables	11	✓ Page 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	<p>✓ Page 11 (a) Describe all statistical methods, including those used to control for confounding</p> <p>✓ Page 11 (b) Describe any methods used to examine subgroups and interactions</p> <p>✓ Page 11 (c) Explain how missing data were addressed</p> <p>(d) If applicable, explain how loss to follow-up was addressed</p> <p>(e) Describe any sensitivity analyses</p>
Results		
Participants	13*	<p>✓ Page 11 (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed</p> <p>✓ Page 11 (b) Give reasons for non-participation at each stage</p> <p>(c) Consider use of a flow diagram</p>
Descriptive data	14*	<p>✓ Page 11 (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders</p> <p>✓ Page 11 (b) Indicate number of participants with missing data for each variable of interest</p> <p>✓ Page 11 (c) Summarise follow-up time (eg, average and total amount)</p>
Outcome data	15*	✓ Page 16 Report numbers of outcome events or summary measures over time
Main results	16	✓ Page 17-19 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which

		confounders were adjusted for and why they were included
		✓ Page 12-15 (b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	✓ Page 16-19 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	✓ Page 20 Summarise key results with reference to study objectives
Limitations	19	✓ Page 21 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	✓ Page 20-21 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	✓ Page 21-22 Discuss the generalisability (external validity) of the study results
Other information		
Funding	22	✓ Page 23 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.